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ABSTRACT 
	  	  
The discovery of the endocannabinoid system propelled understanding of the 
mechanisms of action of cannabinoid compounds. While marijuana is the most widely 
used illicit substance in the world, the neuropsychopharmacological mechanisms that 
underlie the diffuse effects of cannabis in the brain remain poorly understood. This is 
because marijuana smoke represents a complex mixture of chemical components, 
possessing dissociable psychoactive properties. Clinical evidence suggests a functional 
dissociation between the two main pharmacological components of cannabis, Δ9-
tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). Using a combination of cortical 
microinfusions during two emotional learning paradigms, and single-unit in vivo 
electrophysiological recording, we investigated the effects of phytocannabinoid 
compounds in emotional regulation neural circuits, specifically the nucleus accumbens 
shell. We report the first demonstration of hedonic properties of CBD; an effect mediated 
by 5-HT1A receptors, and decreased VTA dopaminergic activity. In olfactory fear 
conditioning, Δ9-THC potentiates and CBD attenuates emotionally salient stimuli similar 
to synthetic cannabinoids.      
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Chapter 1. General Introduction 
In order to coordinate normative cognition and appropriate behavioural responses, the 
brain must accurately process the emotional and motivational significance of an 
enormous amount of incoming sensory stimuli. This requires the formation of adaptive 
learned associations between the emotional salience of sensory inputs with their 
respective environmental cues (Laviolette & Grace, 2006).  
Several cortical and subcortical structures comprise the emotional processing 
circuitry known as the mesocorticolimbic system, including: the medial prefrontal cortex 
(mPFC), the basolateral amygdala (BLA), the ventral tegmental area (VTA) and the 
nucleus accumbens (NAcc). These areas contain high levels of dopamine (DA) and 
cannabinoid CB1 receptors, which are critical in emotional and motivational salience 
processing and associative learning (Herkenham et al., 1991b; Moldrich & Wenger, 
2000). Furthermore, previous research shows that the cannabinoid and DAergic systems 
functionally interact, such that cortical CB1 transmission modulates subcortical 
mesolimbic DA activity (Bossong et al., 2008; Diana, Melis, & Gessa, 1998).  
Activation of the brain’s endocannabinoid system is associated with severe 
distortions in emotional and motivational perceptions and with learning and memory 
impairments (D’Souza et al., 2005). However, delivery of cannabinoids to the brain, via 
drugs such as cannabis, represents a complex mixture of chemical components, 
possessing dissociable psychoactive properties (ElSohly & Slade, 2005; Radwan et al., 
2009). Indeed, recent evidence suggests a functional dissociation between the two main 
pharmacological components of cannabis, cannabidiol (CBD) and Δ9-
tetrahydrocannabinol (Δ9-THC). Furthermore, human brain imaging evidence suggests 
that Δ9-THC and CBD may exert differential psychological effects in distinct 
mesocorticolimbic substrates (Bhattacharyya & Sendt, 2012; Bhattacharyya et al., 2012; 
Bhattacharyya, Fusar-Poli, et al., 2009a; Bhattacharyya, et al., 2009b). The pharmacology 
of these compounds is also quite distinct. CBD has been shown to be a weak antagonist 
of the CB1 receptor (Thomas et al., 2009) as well as an agonist of the serotonin 5-HT1A 
receptor (Russo, Burnett, Hall, & Parker, 2005); in contrast, Δ9-THC acts as a partial 
CB1 agonist (Petitet, Jeantaud, Reibaud, Imperato, & Dubroeucq, 1998). While the 
pharmacological properties of Δ9-THC and CBD are relatively well characterized, the 
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differential effects of these distinct compounds on emotional processing in the brain 
remain poorly understood. Furthermore, there are very few studies investigating the 
effects of distinct Δ9-THC and CBD compounds in specific anatomical structures of the 
brain.  
The work presented in this thesis attempts to address some of the gaps in the current 
understanding of the very complex nature of the major phytocannabinoids (plant-derived) 
in the brain and the effects they have on emotional information processing and memory 
formation. Specifically, this work investigates the dissociable psychoactive effects of Δ9-
THC and CBD microinfusions into the shell subdivision of the NAcc during two 
emotional memory formation paradigms: conditioned place preference (CPP) and 
olfactory fear conditioning. Through a series of behavioural, pharmacological and 
electrophysiological experiments, I have also examined the interactions of these 
compounds with the serotonergic and dopamanergic neurotransmitter systems to reveal 
novel insights into the underlying neurobiological basis of exogenous cannabinoid 
signaling in the mammalian brain. 
 
1.1 The endocannabinoid system 	  
The endocannabinoid (eCB) system is a ubiquitous lipid-based neuromodulatory system 
within the nervous system that has been highly conserved across mammalian species and 
plays diverse roles in normative physiological and psychological functioning (Elphick & 
Egertova, 2001). Two main cannabinoid (CB) receptor subtypes exist in the nervous 
system: the CB1 receptor, which is highly expressed in the central nervous system (CNS), 
and the CB2 receptor which is expressed primarily in peripheral immune cells (Pertwee 
& Ross, 2002). Given the neuroscientific nature of this work, this thesis will focus on 
CB1 receptors. CB1 receptors are primarily expressed on the presynaptic axon terminals 
of glutamatergic principal neurons as well as GABAergic projection and interneurons 
(Katona & Freund, 2012), and are inhibitory G-protein coupled receptors (GPCR). 
Activation of these receptors by their endogenous ligands anandamide (AEA) and 2-
arachidonoylglycerol (2-AG), or by exogenous cannabinoids such as those found in 
cannabis, initiates a number of intra- and extracellular signaling events that serve to 
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inhibit the cell, including: decreasing cytosolic cyclic adenosine monophosphate (cAMP) 
production by inhibiting adenylate cyclase activity, closure of Ca2+ channels, and opening 
of K+ channels (Lupica, Riegel, & Hoffman, 2004; Piomelli, 2003). The CB1 receptor is 
the most ubiquitously expressed GPCR in the brains of both humans (Glass, Dragunow, 
& Faull, 1997) and rats (Herkenham et al., 1991b) and, due to their location on the 
primary excitatory and inhibitory cells in the brain, they play a crucial role in the 
modulation of a number of other neurotransmitter systems including the dopaminergic 
(DA), serotonergic (5-HT), GABAergic and glutamatergic systems (López-Moreno, 
González-Cuevas, Moreno, & Navarro, 2008). The interaction between the eCB and DA 
systems is of particular importance in the consideration of emotional processing and will 
be discussed below.  
1.1.1 Role of CB1 receptors in emotional processing  	  
The eCB system, as mediated by CB1 receptors, plays a central role in the processing of 
emotionally salient stimuli and related behaviours (Laviolette, 2014). The CB1 receptor is 
highly expressed in the striatum, a series of structures involved in emotional and 
motivational information processing, of both rats (Moldrich & Wenger, 2000) and 
humans (Burns et al., 2007). In humans, use of cannabis as well as synthetic cannabinoid 
analogues, both of which act on CB1 receptors, have profound effects on emotional 
processing. Users report a wide array of emotional experiences ranging from euphoria 
and sedation to anxiety, paranoia and agitation. Even acute exposure can result in mood-
related disturbances and alter the significance of external sensory input (Green, 
Kavanagh, & Young, 2003; Rosenbaum, Carreiro, & Babu, 2012; Wachtel, ElSohly, 
Ross, Ambre, & de Wit, 2002). In animal studies, mice lacking the CB1 receptor show 
impairments in extinction learning of an aversive conditioned fear memory (Cannich et 
al., 2004; Marsicano et al., 2002), and display an abnormal emotional phenotype 
characterized by heightened aggressive, depressive and anxiety responses, in some 
behavioural stress paradigms (Martin, Ledent, Parmentier, Maldonado, & Valverde, 
2002). Pharmacological manipulations of CB1 receptors in various regions of the 
mesocorticolimbic system also result in profound alterations of the salience of incoming 
sensory stimuli. In olfactory fear conditioning experiments, rats receive an electric 
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footshock during presentation of one of two distinct odours. Rats receiving intra-mPFC 
microinfusions of the CB1 receptor agonist WIN-55,212-2 (WIN-55) prior to 
conditioning with a normally non-salient subthreshold footshock display heightened 
levels of freezing in response to the shock-paired odour, a measure of conditioned fear. 
This effect was completely abolished using the CB1 receptor antagonist AM-251 
(Laviolette, 2006). CB1 receptor transmission within the BLA—mPFC pathway is also 
critical for the acquisition of emotionally salient associative memories. CB1 receptor 
antagonism, administered systemically and as targeted microinfusions, blocks both the 
behavioural acquisition of conditioned fear memories and LTP along the BLA—mPFC 
pathway, a correlate of exposure to emotionally salient events (Tan, Lauzon, Bishop, 
Bechard, & Laviolette, 2010).  Follow-up electrophysiology studies show a bidirectional 
effect of CB1 receptor modulation in the BLA, with mPFC neurons showing increased 
neuronal activity in response to intra-BLA CB1 activation, and a decrease in activity 
following CB1 antagonism (Tan et al., 2011). The studies outlined above serve to 
illustrate the central role of CB1 receptors in the emotional processing structures of the 
mesocorticolimbic pathway, however cannabinoid transmission within the NAcc remains 
poorly understood and represents a potentially productive avenue of future research.  
 
1.1.2 eCB interactions with the dopamine system 	  
DAergic signaling also plays a critical role in emotional regulation and coordinated 
behaviour in response to emotionally salient stimuli (Laviolette, 2007). While DA 
receptors are expressed throughout the CNS, they display high levels of expression in the 
limbic regions of the brain, suggesting a central role of DA in emotional and motivational 
processes (Wise, 2004). Of particular note are DA efferents originating in the VTA that 
project to higher level cortical structures of emotional regulation including the NAcc, 
BLA and PFC (Grace, Floresco, Goto, & Lodge, 2007; Ikemoto, 2007). There are 
profound anatomical and functional interactions between the eCB and DAergic systems. 
CB1 receptors are expressed in the substantia nigra and striatum, regions that are highly 
innervated by DAergic projections and express high levels of the DA receptor (Moldrich 
& Wenger, 2000). Medium spiny neurons (MSN), the primary output neurons of the 
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striatum, also express both CB1 and DA receptors (Glass & Felder, 1997; Herkenham et 
al., 1991b). Furthermore, substantial evidence suggests that the CB1 and DA receptors 
are coexpressed on synaptic terminals (Chiu, Puente, Grandes, & Castillo, 2010), and 
may even form CB1-DA heterodimer receptor complexes in some brain regions (Kearn, 
2005). These data suggest that CB1 signaling may act as an important modulator of 
DAergic transmission in emotional regulation circuits (Giuffrida et al., 1999).  
Functionally, CB1 receptor modulation has been shown to play an important role 
in DAergic transmission. Systemic administration of CB1 receptor agonists such as Δ9-
THC and WIN-55 increase DAergic neuronal activity in the VTA (Diana et al., 1998; 
French, Dillon, & Wu, 1997), and also enhance the firing rate of PFC pyramidal neurons 
to the VTA (Pistis, Porcu, Melis, Diana, & Gessa, 2001). Furthermore, a recent study 
found that Δ9-THC and WIN-55 administration increase DA synthesis in key emotional 
processing regions such as the dorsal striatum, NAcc, PFC and amygdala (Polissidis et 
al., 2009), suggesting an active role of eCB transmission in the synthesis and activity of 
subcortical DA signaling.  
 
1.1.3 The eCB system in neuropsychiatric disorders 	  
Given the importance of the eCB system in emotional information processing, it is not 
surprising that dysfunctions in the eCB system have been implicated in a range of 
neuropsychiatric disorders that are characterized by deficits in emotional regulation 
(Parolaro, Realini, Viganò, Guidali, & Rubino, 2010). Much of the evidence supporting 
this hypothesis comes from studies using CB1 receptor knockout (KO) animals. Mice 
lacking the CB1 receptor show increased anxiety responses in response to chronic stress 
(Martin et al., 2002), and display a depressive phenotype in the forced swim test (Steiner 
et al., 2008) and tail suspension test (Aso et al., 2008), both behavioural models of 
depression. CB1 KO animals also exhibit elevated serum levels of glucocorticoids 
(Urigüen, Pérez-Rial, Ledent, Palomo, & Manzanares, 2004), suggesting dysfunction of 
the hypothalamus-pituitary-adrenal (HPA) axis, a physiological correlate found in major 
depressive disorder (Pariante & Lightman, 2008; Stokes, 1995), anxiety (Pariante, 2003) 
and post-traumatic stress disorder (PTSD; Yehuda, 2002).  
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Deficits in circulating eCB levels are also observed in these disorders, further 
implicating eCB system dysfunction. Basal serum levels of AEA and 2-AG have been 
found to be significantly lower in individuals diagnosed with major depressive disorder in 
comparison to healthy controls (Hill, Miller, Carrier, Gorzalka, & Hillard, 2009). The 
same group has shown the plasma levels of 2-AG are also significantly reduced in a 
population of PTSD patients in comparison to normal controls (Hill et al., 2013).   
Evidence from pharmacological studies also provides compelling evidence for the 
role of the eCB system in various neuropsychiatric disorders. Both systemic injections 
and targeted microinfusions of CB1 agonists into specific brain regions critically 
involved in emotional processing have been found to be effective at reversing depressive-
like behaviours in various animal models (Bambico, Katz, Debonnel, & Gobbi, 2007; 
Hill & Gorzalka, 2005). Furthermore, pharmacological inhibition of fatty acid amide 
hydrolase (FAAH), the enzyme responsible for degrading the endogenous AEA, shows 
efficacy as an antidepressant and anxiolytic (Bortolato et al., 2007; Haller et al., 2009; 
Scherma et al., 2008), further supporting the hypothesis that a reduction in eCB tone, in 
addition to CB1 receptor deficits, may underlie depressive and anxiety-related symptoms. 
 
1.1.4 Schizophrenia  	  
There is also substantial evidence for severe dysfunction of the eCB system in individuals 
suffering from schizophrenia. This dysfunction manifests both at the level of the CB1 
receptor as well as a dysregulation of eCB tone. In addition, heavy cannabis use 
constitutes a significant environmental risk factor for the development of schizophrenia 
and related psychotic disorders (this will be discussed in more detail below, see section 
1.2.1).  
Neuroanatomical studies have revealed that the CB1 receptor is highly expressed 
in brain regions implicated in the pathophysiology of schizophrenia including the PFC, 
hippocampus, basal ganglia and anterior cingulate cortex (Glass et al., 1997). More recent 
studies suggest that expression of the CB1 receptor in these areas may be altered in 
schizophrenia. Binding of the cannabinoid radioligand [3H]CP55940 to the CB1 receptor 
was shown to be higher in the dorsolateral-PFC of schizophrenic patients than in healthy 
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controls (Dean, Sundram, Bradbury, Scarr, & Copolov, 2001). Dalton et al. (2011) 
subsequently confirmed these findings and additionally provided evidence that CB1 
receptor expression is significantly higher in paranoid schizophrenics as compared to 
non-paranoid schizophrenics and healthy controls. Furthermore, both the anterior and 
posterior cingulate cortex (ACC and PCC, respectively) display increased CB1 receptor 
expression in individuals suffering from schizophrenia in comparison to normal controls 
(Newell, Deng, & Huang, 2006; Zavitsanou, Garrick, & Huang, 2004). Studies 
employing pharmacological manipulation of the eCB system also support a role for the 
CB1 receptor in schizophrenia. Administration of the CB1 receptor agonist WIN-55 
results in impairments in sensorimotor gating such as prepulse inhibition (PPI), an 
information processing and attentional deficit that is evident in patients with 
schizophrenia (Martin et al., 2003; Schneider & Koch, 2002). Furthermore, 
administration of CB1 receptor agonists such as Δ9-THC, the main psychoactive 
ingredient in cannabis, can produce a constellation of effects in humans that are 
reminiscent of schizophrenic symptomatology (Bhattacharyya et al., 2012; Green et al., 
2003; Wachtel et al., 2002) and elicit hyperactivity of mesolimbic DA circuits (Diana et 
al., 1998; French et al., 1997), a core pathophysiologcial feature of schizophrenia (see 
section 1.2.1). These data suggest that dysfunction of the CB1 receptor may play a critical 
role in the aberrant emotional processing observed in schizophrenia. Finally, there is 
evidence to suggest that polymorphisms in the gene coding the CB1 receptor (CNR1) 
may be correlated with an increased susceptibility to developing schizophrenia 
(Chavarría-Siles et al., 2008), although the nature of this relationship is not fully 
understood (Seifert, Ossege, Emrich, Schneider, & Stuhrmann, 2007).   
Dysregulation of eCB tone is also evident in schizophrenia. In a population of 
first-episode paranoid schizophrenic patients, researchers found a significant elevation in 
cerebrospinal fluid levels of AEA as compared to healthy controls (Giuffrida et al., 2004; 
Leweke, Giuffrida, Wurster, Emrich, & Piomelli, 1999), and clinical remission was 
associated with a significant reduction in AEA levels (De Marchi et al., 2003). There is 
also some evidence from animal studies, using a PCP model of schizophrenia, of 
increased AEA levels in some brain regions (Seillier, Advani, Cassano, Hensler, & 
Giuffrida, 2009; Viganò et al., 2008). Somewhat paradoxically, clinical studies have 
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shown that AEA levels are inversely correlated with the severity of psychotic symptoms 
suggesting that elevated eCB tone may be a compensatory adaptation in response to 
abnormal neurotransmission in schizophrenia-related psychoses (Giuffrida et al., 2004; 
Leweke et al., 2012).  
 
1.2 Cannabis and phytocannabinoids  	  
Although cannabis has been used for spiritual, medicinal and industrial purposes for 
thousands of years, it wasn't until the isolation of Δ9-tetrahydrocannabinol (Δ9-THC), the 
major psychoactive cannabinoid in cannabis, in 1964 that scientific understanding of 
phytocannabinoids (plant-derived) truly began (Mechoulam & Gaoni, 1964). In 1990, a 
group of researchers elucidated the structure and expression of an endogenous 
cannabinoid receptor, which was dubbed the CB1 receptor (Matsuda, Lolait, Brownstein, 
Young, & Bonner, 1990), indicating an endogenous target on which Δ9-THC acts in the 
brain. This was quickly followed by the discovery of arachidonylethanolamide (AEA), 
also known as “anandamide”, an endogenous ligand for the CB1 receptor (Devane et al., 
1992). Since these discoveries, research interest in the endocannabinoid system has 
accelerated dramatically and the endocannabinoid system has been implicated in a wide 
range of physiological and psychological functions (Elphick & Egertova, 2001).  
However despite these advances, the neurobiological mechanisms through which 
cannabis exerts its neuropsychological effects, especially at the level of discrete neural 
circuits, remains poorly understood. This is in part because cannabis contains hundreds of 
chemical compounds and over 70 known cannabinoids, each with distinct, dissociable 
and complex pharmacological profiles (ElSohly & Slade, 2005; Radwan et al., 2009). 
The two predominant cannabinoid compounds contained in cannabis are the psychoactive 
Δ9-THC and the non-psychoactive cannabidiol (CBD; Russo & Guy, 2006), which will 
be the focus of the work presented in this thesis.  Recent basic and clinical evidence 
suggests that these two compounds have very different pharmacological profiles and 
dissociable neuropsychological properties (Bhattacharyya et al., 2009b). While Δ9-THC 
administration generally produces subjective states of anxiety and agitation 
(Bhattacharyya et al., 2012; Fusar-Poli et al., 2009), CBD has potent anxiolytic, and 
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antipsychotic effects (Bhattacharyya et al., 2009a; Crippa et al., 2003; Crippa et al., 2010; 
Schubart et al., 2013; Zuardi et al., 2012). Although the neurobiological basis for these 
dissociable effects is not fully understood, it is likely a result of significant 
pharmacological differences between Δ9-THC and CBD. While Δ9-THC is a partial 
agonist of the CB1 receptor (Petitet et al., 1998), CBD is a weak CB1 receptor antagonist 
(Thomas et al., 2009), and displays relatively high binding affinity for serotonin 5-HT1A 
receptors (Russo et al., 2005). CBD also displays antagonistic properties at the putative 
new cannabinoid receptor GPR-55 (Ryberg et al., 2009), and is an effective inhibitor of 
FAAH, and thus indirectly increases AEA tone  (Bisogno et al., 2001).  
 
1.2.1 Cannabis use as a risk factor for schizophrenia 	  
The link between cannabis use and an increased risk of developing schizophrenia is well 
established in the scientific literature (Bossong & Niesink, 2010; Semple, 2005; Smit, 
Bolier, & Cuijpers, 2004; Wilkinson, Radhakrishnan, & D’Souza, 2014). A seminal 1987 
study established a correlation between lifetime prevalence of cannabis use and an 
increased likelihood of developing schizophrenia later in life (Andersson et al., 1987). 
Since then, numerous longitudinal studies have explored the nature of this relationship. In 
general, the main findings demonstrate that while cannabis use alone is neither necessary 
nor sufficient to induce psychotic disorders, prolonged and excessive use especially 
during critical developmental periods of adolescence represents a significant risk factor in 
individuals genetically and environmentally predisposed to developing psychotic 
disorders and other mental illnesses (Wilkinson et al., 2014). Indeed, neuroimaging 
studies have found that individuals who start using cannabis before 17 years of age show 
reductions in cortical grey matter and increased percentage of white matter in comparison 
to those who initiate use later (Wilson et al., 2000). Other imaging studies show that 
chronic cannabis users also display reduced hippocampal and amygdalar volumes in 
comparison to non-using controls (Yücel et al., 2008). Both cortical grey matter 
reductions and structural abnormalities in hippocampal and amygdalar structures are  
commonly observed pathophysiological features of schizophrenia (Ellison-Wright & 
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Bullmore, 2009), however whether these neural alterations are a cause or effect of early 
and extensive cannabis use has yet to be elucidated.  
Additional evidence for the association between cannabis and schizophrenia 
comes from challenge studies involving acute administration of Δ9-THC or other 
cannabinoids, in healthy and schizophrenic individuals. In healthy volunteers, acute Δ9-
THC exposure has been shown to transiently induce a range of psychotomimetic 
symptoms reminiscent of those observed in schizophrenia, including cognitive and 
attentional impairments as well as feelings of paranoia and anxiety (Bhattacharyya et al., 
2012; Bhattacharyya et al., 2009a; D’Souza et al., 2012). In individuals with a confirmed 
diagnosis of schizophrenia, treatment with Δ9-THC resulted in a transient exacerbation of 
core psychotic symptoms, cognitive deficits and perceptual alterations (D’Souza et al., 
2005). Interestingly, studies investigating the effects of CBD show starkly opposite 
results to those found with Δ9-THC treatment. In contrast to Δ9-THC, CBD 
administration does not elicit any psychotomimetic effects, and is not associated with 
perceptual alterations or cognitive deficits in healthy volunteers (Bhattacharyya et al., 
2009b). In individuals with schizophrenia, CBD actually displays antipsychotic efficacy 
comparable to conventional antipsychotic medications (Leweke et al., 2012), likely due 
to its ability to inhibit FAAH and indirectly elevated endogenous levels of AEA 
(Giuffrida et al., 2004; Leweke et al., 1999). 
The relationship between cannabis use and schizophrenia is thus complex and 
further investigation is needed to elucidate the neurobiological mechanisms underlying 
this association.  
 
1.3 Research Purpose and Hypotheses 	  
The studies reviewed above illustrate the central role of the eCB system in emotional 
processing circuits, specifically within the mesocorticolimbic system, and describe how 
dysfunctions in this system may represent a neurobiological mechanism that contributes 
to the development of various neuropsychiatric disorders. However, little is known about 
the role that CB1 receptor signaling within the NAcc plays in the processing of appetitive 
and aversive emotional stimuli, specifically in response to phytocannabinoid 
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administration. The work presented in this thesis attempts to address this, by pursuing the 
following objectives: 
 
Objective 1: To characterize the reinforcing properties of intra-NASh CBD 
microinfusions in an unbiased conditioned place preference paradigm.  
 
Objective 2: To characterize the behavioural effects of intra-NASh Δ9-THC and 
CBD microinfusions during the encoding and recall of emotionally aversive 
associative learning.   
 
 Based on clinical data, work from our own laboratory and the distinct pharmacological 
profiles of Δ9-THC and CBD, I hypothesized that these two cannabinoid compounds 
would exhibit dissociable and opposite effects in our behavioural paradigms.  
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Chapter 2. Cannabidiol produces rewarding effects in the nucleus 
accumbens shell via serotonergic and dopaminergic signaling 
mechanisms 
2.1 Introduction 
Marijuana is the most widely used illicit drug in the world (Murray, Morrison, Henquet, 
& Di Forti, 2007; United Nations, 2010) and although our understanding of 
phytocannabinoids is growing, the debate over marijuana’s addiction potential and abuse 
liability remains controversial. While traditionally not considered an addictive drug, 
recent research suggests the presence of distinct marijuana dependence and withdrawal 
syndromes in heavy users (Budney & Hughes, 2006; Ramesh, Schlosburg, Wiebelhaus, 
& Lichtman, 2012).  However, cannabis contains over 70 known cannabinoid 
compounds, each with unique pharmacological properties (ElSohly & Slade, 2005; 
Radwan et al., 2009). Thus, the neuropsychopharmacological mechanism by which 
cannabis, or its constituent compounds, elicits a behaviourally rewarding response 
remains poorly understood.   
Indeed, emerging clinical evidence suggests a functional dissociation between the two 
main pharmacological components of cannabis, the psychoactive Δ9-
tetrahydrocannabinol (Δ9-THC) and the non-psychoactive cannabidiol (CBD), in distinct 
mesocorticolimbic substrates (Bhattacharyya et al., 2012; Bhattacharyya, Fusar-Poli, et 
al., 2009a; Bhattacharyya et al., 2009b; Fusar-Poli et al., 2009). While Δ9-THC exhibits 
propsychotic effects (Bhattacharyya et al., 2012), CBD displays antipsychotic (Leweke et 
al., 2012; Mechoulam, Peters, Murillo-Rodriguez, & Hanus, 2007; Schubart et al., 2013; 
Zuardi et al., 2012; Zuardi, Crippa, Hallak, Moreira, & Guimarães, 2006) and anxiolytic 
(Almeida et al., 2013; Campos & Guimarães, 2008; Casarotto, Gomes, Resstel, & 
Guimarães, 2010; Crippa et al., 2010; Fogaça, Reis, Campos, & Guimarães, 2014) 
properties comparable to conventional antipsychotic medications.  
Cannabinoids exert their neuropsychological effects by acting on the body’s 
endocannabinoid (eCB) system at centralized cannabinoid CB1 receptors. Both Δ9-THC 
and CBD resemble endogenous CB1R ligands, however their pharmacology is distinct. 
Furthermore, in situ hybridization studies show high levels of colocalization between 
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CB1 receptors and dopaminergic (DA) and serotonergic (5-HT) receptors, suggesting the 
eCB system may play a crucial role in modulating activity of these systems (Hermann, 
Marsicano, & Lutz, 2002; Maroteaux et al., 1992).   
Until recently, research efforts have focused almost exclusively on determining the 
reinforcing properties of Δ9-THC with mixed results (see Tzschentke, 2007 for a review). 
Animal studies reveal rewarding and aversive effects of Δ9-THC in the conditioned place 
preference and self-administration paradigms (Gardner, 2002; Tanda & Goldberg, 2003; 
Valjent & Maldonado, 2000). However, there is little evidence that CBD itself possesses 
hedonic properties (Parker, Burton, Sorge, Yakiwchuk, & Mechoulam, 2004). The aim of 
the current study was to investigate the potential psychoactive properties of CBD in 
discrete anatomical regions of the mesocorticolimbic circuitry. Specifically, we 
conducted a series of behavioural pharmacological experiments examining the rewarding 
effects of CBD microinfusions into the shell subdivision of the nucleus accumbens 
(NASh), a structure which highly expresses CB1 receptors (Fusco et al., 2004; 
Herkenham, Lynn, de Costa, & Richfield, 1991a; Moldrich & Wenger, 2000) and is 
sensitive to synthetic cannabinoid reward in animal models (Mahler, Smith, & Berridge, 
2007; Zangen, Solinas, Ikemoto, Goldberg, & Wise, 2006). We report here the first 
evidence of the hedonic psychoactive properties of CBD in a conditioned place 
preference paradigm.  
 
2.2 Materials and Methods 
2.2.1 Animals and Surgery 
Male Sprague Dawley rats (300-350g) were obtained from Charles River Laboratories 
(Quebec, CAN). Rats were anesthetized with an intraperitoneal (i.p.) injection of a 
ketamine (80mg/ml)-xylazine (6mg/kg) mixture and meloxicam (1.0 mg/kg; s.c.) was 
administered preoperatively in order to reduce pain and post-surgical inflammation. 
Following an assessment of anesthetic depth, rats were immobilized using a Kopf 
stereotaxic device. Using sterile technique, an incision was made to expose the skull.  
Guide cannulae (22-gauge) were implanted bilaterally into the NASh using flat skull 
stereotaxic coordinates as follows (12o angle, in mm from bregma): anteroposterior (AP) 
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+ 1.8, lateral (LAT) ± 2.6, ventral (V) -7.4 from the dural surface. Cannulae were 
implanted in the VTA using the following stereotaxic coordinates (10o angle, in mm from 
bregma): anteroposterior (AP) + 1.8, lateral (LAT) ± 2.6, ventral (V) -8.0 from the dural 
surface. All stereotaxic coordinates were based upon the atlas of Paxinos and Watson 
(1996). Cannulae were secured to the skull using four small jeweler’s screws and dental 
acrylic. Dust-caps were used to ensure the patency of the cannulae.  All procedures were 
performed in accordance with the Canadian Council on Animal Care (CCAC) and were 
approved by Western University’s Council on Animal Care. 
 
2.2.2 Post-Surgery SOP 
Rats were injected subcutaneously with 3 – 10 mL of physiological saline in order to 
prevent dehydration. Rats recovered in a clean home cage filled with wood shavings and 
warmed under a heat lamp. Behaviour was monitored until recovery from the anesthetics 
and sternal recumbency attained.  A maintenance dose of meloxicam (1.0 mg/kg) was 
administered (s.c.) 24 hours post-surgery in order to reduce pain and inflammation. 
Following at least one week of recovery, rats were then tested in behaviorual paradigms.  
 
2.2.3 Conditioned Place Preference  
All rats were conditioned using an unbiased, fully counterbalanced conditioned place 
preference (CPP) procedure, as described previously (Laviolette & van der Kooy, 2003; 
Laviolette, Nader, & van der Kooy, 2002). Rats received drug microinfusions, and were 
then conditioned in one of two environments that differed in colour, texture and scent. 
One environment was black constructed with a smooth Plexiglas floor, wiped down with 
2% acetic acid solution before each conditioning session. The other environment was 
white with a wire mesh floor covered with wood chips. Rats display no baseline 
preference for either of these two environments (Laviolette & van der Kooy, 2003). Rats 
were preconditioned (24 hrs prior to conditioning) in a motivationally neutral grey box 
for 30 min, in order to minimize stress during behavioural conditioning. Immediately 
prior to conditioning, rats received intra-NASh microinfusions of CBD (50, 100, 
500ng/0.5µl) alone, or coadministered with the DA antagonist α-flupenthixol (100ng – 
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1.0µg/0.5µl), 5-HT1A antagonist NAD-299 hydrochloride (100 – 500ng/0.5µl), or 5-HT1B 
antagonist GR-55562 (10 – 100ng/0.5µl). For animals implanted with cannulae in the 
NASh and the VTA, the GABAA antagonist bicuculline methiodide (50ng/0.5µl) and the 
GABAB antagonist hydroxysaclofen (100ng/0.5µl), or their respective vehicle, were 
coadministered into the VTA 2 min prior to intra-NASh CBD infusion.   
Following microinfusions, rats were placed in one of the two conditioning 
environments for 30 min. Experimental treatments were counterbalanced such that each 
animal was randomly assigned to receive either drug or vehicle infusions in either the 
white or the black environment. During conditioning, rats received four drug-
environment and four saline-environment conditioning sessions. During testing, rats were 
placed on a narrow, neutral grey zone separating the two test environments and times 
spent in each environment was digitally recorded and scored separately for each animal 
over a 10 min test session. All rats were tested in a drug free state.  
 
2.2.4 Drug administration   
The broad-spectrum DA receptor antagonist, α-flupenthixol, the highly specific 5-HT1B 
receptor antagonist, GR-55562, the GABAA antagonist, bicuculline methiodide, and the 
GABAB antagonist, hydroxysaclofen, were dissolved in physiological saline (pH adjusted 
to 7.4). The 5-HT1A receptor antagonist, NAD-299 hydrochloride, and CBD were 
dissolved in dimethyl sulfoxide (DMSO, Fisher Scientific). For NASh and VTA 
microinfusions, stainless steel guide cannulae (22-gauge) were implanted bilaterally into 
the NASh through a 28-gauge microinfusion injector (Plastics One). Bilateral 
microinfusions were performed over 1 min through a Hamilton microsyringe. In order to 
ensure the diffusion of the drug away from the injector tip, the internal cannulae were left 
in place for an additional minute. All drugs were purchased from Tocris Biosciences.  
 
2.2.5 VTA neuronal activity recording 
In vivo single-cell extracellular recordings in the VTA were performed as 
described previously (Tan, Bishop, Lauzon, Sun, & Laviolette, 2009). Briefly, 18 rats 
were anesthetized with urethane (1.4 g/kg, i.p.) and placed in a stereotaxic frame with 
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body temperature maintained at 37°C. A scalp incision was made and a hole was drilled 
in the skull above the NASh and the VTA. For intra-NASh microinfusion of CBD (100 
ng/ 0.5 µL), a 1 µL Hamilton syringe was slowly lowered at the same coordinates used 
for behavioral studies. For intra-VTA extracellular recording, glass micro-electrodes 
(with an average impedance of 6-8 MΩ) filled with a 2% Pontamine Sky Blue solution 
were lowered using a hydraulic micro-positioner (Kopf 640) at the following flat skull 
stereotaxic coordinates (in mm from bregma): anteroposterior (AP) -5.3, lateral (LAT) ± 
0.7 from midline, ventral (V) -7.0 to -8.5 from the dural surface. Extracellular signals 
were amplified using a MultiClamp 700B amplifier (Molecular Devices) and recorded 
through a Digidata 1440A acquisition system (Molecular Devices) using pClamp 10 
software. Extracellular recordings were filtered at 1 kHz and sampled at 5 kHz. VTA DA 
neurons were identified according to well-established electrophysiological features 
(Jalabert et al., 2011; Ungless, Magill, & Bolam, 2004): (1) a relatively long action 
potential width (>2.5 ms); (2) a slow spontaneous firing rate (2 - 5  Hz) (3) a triphasic 
waveform consisting of a notch on the rising phase followed by a delayed after potential; 
and (4) a single irregular or bursting firing pattern. VTA GABA interneurons were also 
characterized based upon previously reported criteria: (1) a narrow action potential width 
(<1 ms), (2) a biphasic waveform; (3) relatively fast firing rates (typically between 10 and 
20 Hz); and (4) the absence of bursting activity. Neurons that failed to clearly meet the 
aforementioned criteria for VTA DA or VTA non-DA electrophysiological neuronal 
properties were excluded from further study.  
Recordings analyses were accomplished using the Clampfit 10 software package. 
The response patterns of isolated VTA neurons to intra-NASh CBD microinfusions were 
determined by comparing the neuronal frequency rates between the 5 min pre-infusion 
versus post-infusion epochs. Classification of drug-infusion effects used a criterion of a ≥ 
10% increase in firing frequency post-infusion to be classified as an “increase” effect; a ≤ 
10 % decrease to be classified as a “decrease” effect. Neurons showing firing frequency 
parameters within these cut-off points were classified as “no change”. Within identified 
VTA DA neurons, we also analyzed the burst rate (number of burst events over time) and 
the number of spikes within each burst. The onset of a burst was defined as the 
occurrence of two consecutive spikes with an inter-spike interval of <80 ms.  
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For histological analysis of extracellular VTA neuronal recording sites, recording 
electrode positions were marked with an iontophoretic deposit of Pontamine Sky Blue 
dye (−20 µA, continuous current for 12–15 minutes).  Then, rats were perfused 
transcardially with isotonic saline followed by 10% formalin. Brains were removed and 
stored in a 25% sucrose-formalin solution before sectioning (40 µm sections) on a 
freezing cryostat. Following this, sections were stained with cresyl violet and infusion 
and/or neuronal recording sites were confirmed with light microscopy. 
2.2.6 Histology 
Following completion of experiments, rats were transcardially perfused, brains were 
extracted and stored in a specimen vial containing formalin with 25% sucrose solution for 
at least 24hrs. The region of the projected cannulae placements were cut into 40 µm 
coronal sections, mounted and stained using cresyl violet to allow for histological 
examination of the injection site. The majority of NASh and VTA placements were 
localized within the region of the shell of the nucleus accumbens or the ventral tegmental 
area, respectively. Rats found to have injectors situated outside the anatomical boundaries 
of the NASh or VTA were excluded from experimental analysis.   
 
2.2.7 Data analysis  
Behavioural data were analyzed with a multivariate ANOVA followed by paired-
samples t-tests or Fisher’s Least Significant Difference (LSD) tests, where appropriate. 
Electrophysiological data were analyzed using a paired-sampled t-test (SPSS Statistics 21 
software) and only values with p ≤ 0.05 were considered as significant.  
 	  
2.3 Results	  
2.3.1 Histological analysis 
Histological analysis revealed microinfusion injector cannulae placements to be 
bilaterally localized within the anatomical boundaries of the shell subdivision of the 
nucleus accumbens and the VTA, according to the Rat Brain Atlas (Paxinos & Watson, 
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1996). Figure 1A presents a microphotograph displaying a typical injector placement 
within the NASh. Figure 1B displays a schematic illustration showing representative 
intra-NASh bilateral cannuale placements along the rostral-caudal axis of the nucleus 
accumbens. Figure 1C shows a microphotograph displaying a typical injector placement 
within the VTA. Figure 1D displays a schematic illustration showing representative intra-
VTA bilateral cannuale placements along the rostral-caudal axis of the ventral tegmental 
area.  Rats with cannulae placements located outside of the NASh or VTA were removed 
from data analysis.  
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Figure 1. Histological analysis of intra-NASh and intra-VTA microinjection sites. A, 
Microphotograph of a representative injector placement within the shell subdivision 
(AcbSh) of the NAcc. B, Schematic representation of select intra-NASh injector 
locations; • = 100ng CBD group,  ♦ = 100ng CBD + 500ng NAD299 group. C, 
Microphotograph of a representative injector placement in the VTA. D, Schematic 
representation of intra-VTA injector locations; ο = 100ng saclofen + 50ng bicuculline. 
 
2.3.2 Intra-NASh CBD microinfusions display behaviourally rewarding properties 
In order to establish a dose-response curve to examine the motivational properties of 
CBD, we performed a conditioned place preference experiment using a range of doses of 
CBD, 50ng (n = 8), 100ng (n = 8), 500ng (n = 6). Multivariate ANOVA revealed a 
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significant effect of treatment, F(4, 36) = 3.38, p = .019. Follow-up paired samples t-tests 
revealed that rats spent significantly more time, t(7) = -5.45, p = .001, in the environment 
paired with 100ng CBD microinfusion (M = 284.10s, SD = 32.99) than the environment 
paired with vehicle administration (M =172.24s, SD = 42.83). In contrast, there were no 
significant differences in the amount of time rats spent in the CBD or vehicle-paired 
environments for the 50ng dose, t(7) = 0.47, p  = .66, or the 500ng dose, t(5) = -0.38, p = 
.72 (see Figure 2).   
Based upon this dose-dependent effect, we chose the highest behaviourally effective dose 
(i.e., 100ng/0.5µl) of CBD for subsequent behvioural experiments. For the sake of 
simplicity, data from all follow-up experimental groups will be compared to the data of 
our 100ng CBD group.  
 
	  
Figure 2. Dose response curve for intra-NASh CBD microinjections. Data represent 
mean (±SEM) time spent in drug- and vehicle-paired environments for rats 
conditioned with intra-NASh CBD. A moderate dose of 100ng/0.5µl CBD produces a 
significant conditioned place preference for the drug-paired environment, suggesting that 
CBD has reinforcing properties in moderate doses.  	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2.3.3 Intra-NASh 5-HT1A receptor blockade switches the motivational valence of 
CBD from rewarding to aversive  
Based on the large body of evidence that implicates the serotonergic system, particularly 
5-HT1A receptors, in the pharmacological action of CBD we challenged our observed 
place preference effect with intra-NASh NAD-299 hydrochloride, a potent 5-HT1A 
antagonist. Multivariate ANOVA revealed a significant effect of treatment, F(6, 46) = 3.29, 
p = .009. Follow-up paired samples t-tests revealed that 100ng NAD-299 (n = 7) was 
effective at blocking the place preference induced by CBD (100ng), t(6) = 0.90, p  = .40. 
At the higher dose of 500ng NAD-299 (n = 6), 5-HT1A antagonism switched CBD’s 
motivational valence from rewarding to aversive, t(5) = 2.682, p  = .044, rats receiving co-
administration of CBD with 500ng NAD-299 spent significantly more time in the 
vehicle-paired environment (M = 327.70s, SD = 67.17) than the CBD-paired environment 
(M = 182.07s, SD = 70.29) (see Figure 3A). In order to rule out the possibility that NAD-
299 may possess aversive properties on its own, we performed a control experiment in 
which rats were conditioned with vehicle or 100ng NAD-299 (n = 7). Paired samples t-
test revealed that rats did not form a significant preference or aversion for either the 
vehicle- (M = 224.09s, SD = 167.89) or NAD-299 (M = 301.03s, SD = 168.74) -paired 
environments, t(6) = -0.607, p  = .57, suggesting that NAD-299 alone is not responsible 
for the conditioned aversion observed with rats receiving 500ng NAD-299 in 
combination with CBD. (see Figure 3A). Post hoc analysis using Fisher’s LSD revealed 
that rats conditioned with 100ng CBD co-administered with 100ng and 500ng NAD-299 
spent significantly (p’s < .05) more time in the vehicle-paired environment (M100ng NAD = 
310.53s, SD100ng NAD = 146.71; M500ng NAD = 327.70s, SD500ng NAD = 67.17) compared to rats 
conditioned with 100ng CBD alone (M = 172.24, SD = 42.83). 
 
2.3.4 Intra-NASh 5-HT1B receptor antagonism blocks the acquisition of CBD reward 
memory   
Given our results with 5-HT1A receptor antagonism, and based upon evidence showing 
that CB1 receptors are colocalized with 5-HT1B receptors, we next examined whether 
blockade of intra-NASh 5-HT1B receptors would yield similar results. In a separate 
experiment, rats were conditioned with CBD (100ng) co-administered with GR-55562 
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dihydrochloride, a potent 5-HT1B antagonist. Multivariate ANOVA revealed a significant 
effect of treatment, F(4, 36) = 3.29, p = .021. Follow-up t-tests revealed that intra-NASh 5-
HT1B antagonism was effective at blocking CBD-induced place preference at a dose of 
10ng (n = 7), t(6) = 0.558, p  = .60, and 100ng (n = 7), t(6) = -0.176, p  = .87. Post hoc 
analysis using Fisher’s LSD revealed that rats conditioned with 100ng CBD co-
administered with 10ng GR-55562 spent significantly (p = .044) more time in the 
vehicle-paired environment (M = 290.53s, SD = 141.23) compared to rats conditioned 
with 100ng CBD alone (M = 172.24, SD = 42.83) (see Figure 3B). Together, these data 
suggest that serotonergic transmission at both 5-HT1A and 5-HT1B receptors is necessary 
for the behaviourally hedonic properties of CBD.  
 
	  
Figure 3. Intra-NASh 5-HT antagonism blocks CBD reward memory acquisition. A, 
Intra-NASh 5-HT1A antagonism with 100ng/0.5µl NAD299 is sufficient to block 
A) 
B) 
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acquisition of CBD reward memory, while 500ng/0.5µl NAD299 switches CBD’s 
motivational valence from rewarding to aversive. Intra-NASh NAD299 alone does not 
produce a preference or an aversion. B, Intra-NASh 5-HT1B antagonism (10ng and 
100ng/0.5µl) is sufficient to block acquisition of intra-NASh CBD reward memory. 
 
2.3.5 Intra-NASh DA receptor antagonism blocks the acquisition of CBD reward 
memory   
Given that most drugs of abuse evoke phasic DA release from the VTA, we challenged 
our behaviourally effective dose of CBD (100ng) with α-flupenthixol (α-flu), a broad 
spectrum DA antagonist, in order to block signaling from DAergic VTA projections to 
the NASh. Although CBD is not known to interact with the DAergic system, multivariate 
ANOVA revealed a significant effect of treatment, F(4, 46) = 6.93, p = .00. Follow-up t-
tests revealed that intra-NASh DA antagonism was effective at blocking CBD-induced 
place preference at a dose of 100ng (n = 9), t(8) = -1.26, p  = .24, and 1.0µg (n = 10), t(9) = 
-1.06, p  = .32. Rats conditioned with CBD co-administered with 100ng or 1.0µg α-flu 
did not develop significant preferences for either the CBD- or vehicle-paired 
environments (see Figure 4). Thus, the data suggest that acquisition of CBD reward 
memory is dependent on intra-NASh DAergic transmission, presumably originating from 
VTA projections.  
 
 
 
 
 
 
 
 
 
 
Figure 4. Intra-NASh DA antagonisms blocks acquisition of CBD reward meory. Intra-NASh 
DA antagonism with α-flupenthixol (100ng and 1.0µg/0.5µl) is sufficient to block acquisition of 
intra-NASh CBD reward memory. 
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2.3.6 Intra-NASh CBD decreases DAergic neuronal activity in the VTA 
In order to test the hypothesis that intra-NASh CBD elicits phasic increases in VTA DA 
release, we performed in vivo electrophysiology experiments in which the rewarding dose 
of CBD (100ng) was microinfused into the NASh while simultaneously recording single-
cell extracellular neuronal activity in the VTA. A total of 15 VTA-DA neurons were 
recorded and analyzed following intra-NASh CBD microinfusion. A cell was considered 
to have changed its firing rate if there was a minimum of 10% difference from baseline. 
According to this criterion, 60% (n = 9) of DA neurons showed a decrease in activity, 7% 
(n = 1) showed an increase, and 33% (n = 5) demonstrated no change in activity levels. 
Statistical analyses of the average frequency recorded during the 5min before and 5min 
after the intra-NASh microinfusion showed that CBD significantly decreased the activity 
of VTA DA neurons (t(14) = 3.13, p < 0.01). Furthermore, bursting analysis revealed that 
CBD significantly reduced the number of burst events over time (t(14) = 2.76, p < 0.05) 
without significantly decreasing the number of spikes within each burst (t(14) = 2.06, p = 
0.06) (see Figure 5). Taken together, these data suggest that CBD (100 ng) microinfused 
in the NASh induces an inhibition of VTA-DA neuronal activity. The reduction of the 
firing frequencies and burst events suggest that the tonic and phasic release of DA in the 
NASh are reduced following the microinfusion of CBD. 
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Figure 5. Intra-NASh CBD decreases DAergic neuronal activity in the VTA. A, 
Representative rastergram showing firing frequency patterns of sampled VTA DAergic 
neurons during intra-NASh CBD microinfusion. VTA DAergic neuronal recording 
sample demonstrates a typical decrease in neuronal activity following intra-NASh CBD 
(100ng/0.5µl). B, Number of DAergic cells sampled, 60% of cells decreased neuronal 
activity, 33% displayed no change in activity, and 7% exhibited an increase in activity. C, 
Frequency (Hz) of VTA DAergic cell firing before and after intra-NASh microinfusion. 
Following CBD administration, cells display a significant reduction in firing frequency. 
D, Number of burst events per minute of VTA DAergic cells before and after intra-NASh 
CBD microinfusion. Following CBD administration, there is a significant reduction in the 
number of burst events per minute. 
 
 
2.3.7 Intra-NASh CBD modulates GABAergic neuronal activity in the VTA 
We found that CBD (100ng) was able to significantly decrease VTA DAergic neuronal 
activity. GABA interneurons are one of the major sources of inhibitory neurotransmitters 
within the VTA and are known to control reward signaling between DAergic and non-
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DAergic neural motivational systems (Laviolette & van der Kooy, 2001). As a result, it is 
highly probable that the observed CBD effect on VTA DAergic cell activity was due to 
an increase in VTA GABA interneuron activity. To test this hypothesis, we recorded and 
analyzed VTA GABA neurons (n = 15) before and after a microinfusion of CBD (100 
ng) into the NASh. Analysis of the general activity changes revealed that 27% (n = 4) of 
interneurons decreased their activity, 40% (n = 6) of interneurons increased their activity, 
and 33% (n = 5) demonstrated no change in activity levels. Statistical analyses of the 
frequencies recorded during the 5 min before and 5 min after the intra-NASh 
microinfusion showed that CBD did not significantly modify the average firing frequency 
of VTA GABA interneurons, t(14) = -0.04; p = 0.97. Collectively, these data suggest that 
CBD microinfused in the NASh induce heterogeneous effects on VTA GABA cells (see 
Figure 6). However, the majority of interneurons (40%) increased their firing. Therefore, 
it seems reasonable that the effect of CBD on VTA DAergic neuronal activity was 
attributable to the sub-population of GABA cells that increased their firing frequency. 
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Figure 6. Intra-NASh CBD modulates GABAergic interneuron neuronal activity in 
the VTA. A, Representative rastergram showing firing frequency patterns of sampled 
VTA GABAergic neurons during intra-NASh CBD microinfusion. VTA GABAergic 
neuronal recording sample demonstrates a typical decrease in neuronal activity following 
intra-NASh CBD (100ng/0.5µl). B, Representative rastergram showing firing frequency 
patters of sampled VTA GABAergic neurons during intra-NASh CBD microinfusion. 
VTA GABAergic neuronal recording sample demonstrates a typical increase in neuronal 
activity following intra-NASh CBD (100ng/0.5µl). C, Number of GABAergic cells 
sampled, 27% of cells decreased neuronal activity, 33% displayed no change in activity, 
and 40% exhibited an increase in activity. D, Frequency (Hz) of VTA GABAergic cell 
firing before and after intra-NASh microinfusion. Following CBD administration, the 
subpopulation of cells that demonstrated an increase in neuronal activity displayed a 
significant increase in firing frequency following intra-NASh CBD. 
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2.3.8 Intra-VTA GABAA/B receptor antagonism blocks the acquisition of intra-
NASh CBD reward memory 
In order to further investigate the effects of CBD’s modulation of VTA GABAergic 
activity at the behavioural level, we performed experiments in which rats were bilaterally 
implanted with cannulae into both the NASh and VTA.  Rats received infusions of intra-
NASh CBD (100ng) and a combination of intra-VTA bicuculline (50ng) and saclofen 
(100ng) in order to antagonize both GABAA and GABAB receptors in the VTA. Rats 
were then conditioned in the CPP protocol outlined above. A paired samples t-test 
revealed intra-VTA GABAA/B antagonism blocked the acquisition of intra-NASh CBD 
reward memory, t(8) = 1.42, p =.195. Rats did not spend significantly more time in the 
CBD-paired environment (M = 209.95, SD = 139.32) compared to the vehicle-paired 
environment (M = 343.41, SD  = 145.03). An independent samples t-test revealed that 
rats conditioned with intra-VTA GABAA/B antagonists spent significantly more time in 
the vehicle-paired environment (M = 343.41, SD = 145.03) compared to rats conditioned 
with intra-NASh CBD alone (M = 172.24, SD = 42.83), t(15) = -3.379, p = .007. In 
contrast independent samples t-test revealed that rats conditioned with intra-VTA 
GABAA/B antagonists did not spend significantly more time in the drug-paired 
environment (M = 209.95, SD = 139.32) compared to rats conditioned with intra-NASh 
CBD alone (M = 284.10, SD = 32.99), t(15) = 1.55, p = .156. These data indicate that 
antagonism of VTA GABAA/B receptors blocks the acquisition of intra-NASh CBD 
reward memory (Figure 7). Together with our electrophysiology data, these results 
suggest that a reduction in VTA DAergic signaling due to a general increase in VTA 
GABAergic interneuron activity is necessary for the acquisition of intra-NASh CBD 
reward memory. By blocking GABAA/B receptors in the VTA, GABA interneurons are 
unable to suppress DAergic projection neurons to the NASh. Thus, the intra-NASh CBD-
induced decrease in VTA DAergic activity is blocked, and the behavioural reward effect 
is abolished.      	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Figure 7. Intra-VTA GABAA/B antagonism blocks acquisition of intra-NASh CBD 
reward memory.  Intra-VTA antagonism of GABAA receptors, with bicuculline 
(50ng/0.5µl), and GABAB receptors, with saclofen (100ng/0.5µl), is sufficient to block 
acquisition of intra-NASh CBD reward memory. 
 
 
 
2.4 Discussion	  
This work represents the first demonstration that cannabidiol does indeed possess 
reinforcing psychoactive properties in the shell of the nucleus accumbens (NASh) at both 
the behavioural and electrophysiological levels. Intra-NASh CBD microinfusions 
produced a significant place preference reward memory in an unbiased CPP paradigm. 
This effect was dependent on 5-HT1A, 5-HT1B and DA receptor signaling within the 
NASh, and elicited a modulation of DAergic and GABAergic neuronal activity within the 
VTA.  
     	  
2.4.1 Intra-NASh CBD produces a reward memory in a dose-dependent manner	  
The conditioned place preference paradigm is an animal model for investigating the 
rewarding or aversive properties of various chemical compounds. It has particular utility 
when examining the effects of drugs of abuse, because of the many parallels it shares 
with human drug use. Both humans and animals will seek out environmental cues that 
have been associated with drug administration and for many addicts coming into contact 
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with cues that predict drug use (e.g., drug paraphernalia, a particular spatial location 
where drugs were used), can be major contributing factors to relapse (Carter & Tiffany, 
1999; Young et al., 2014). In addition, many drugs of abuse, such as nicotine (Laviolette 
& van der Kooy, 2004; Tan et al., 2009), alcohol (Philpot, Badanich, & Kirstein, 2003), 
and cannabinoids (Katsidoni, Kastellakis, & Panagis, 2013), exhibit dose-dependent 
effects in animal models such as CPP. 	  
The current study is the first to systematically establish a dose-response curve for 
the rewarding properties of CBD using a CPP paradigm. Our results show that while very 
low (50ng) and very high (500ng) doses of CBD did not produce any appetitive or 
aversive effects, a moderate dose of CBD (100ng) produced a significant preference for 
the environment paired with intra-NASh CBD microinfusions (Figure 2). These data 
suggest that CBD does possess hedonic psychoactive properties and may give us insight 
into the behavioural and cellular mechanisms that precipitate and maintain cannabis 
abuse.	  	  
2.4.2 CBD reward signals through 5-HT receptor transmission in the NASh 	  
In addition to its antagonistic action at CB1 receptors, CBD has been shown to have 
agonistic properties at serotonin (5-HT) receptors, particularly at 5-HT1A receptors 
(Russo et al., 2005). We therefore performed experiments to investigate whether the 
observed rewarding effect of CBD was dependent on 5-HT1A receptor transmission 
within the NASh. We found that co-administration of CBD with NAD-299, a 5-HT1A 
receptor antagonist, was able to block CBD reward memory acquisition at the low dose 
(100ng). However, at the high dose (500ng), 5-HT1A receptor antagonism switched 
CBD’s motivational valence from rewarding to aversive (Figure 3A). Together these data 
suggest that 5-HT1A signaling is crucial for the hedonic properties of intra-NASh CBD, 
and that a decrease in 5-HT1A signaling may precipitate an aversive response. Recent 
studies implicate the 5-HT1A receptor as playing a critical role in the anxiolytic, 
antidepressant and antipsychotic actions of CBD (Almeida et al., 2013; Campos & 
Guimarães, 2008; Campos, Ferreira, & Guimarães, 2012; De Almeida & Mengod, 2008; 
Fogaça et al., 2014; Zanelati, Biojone, Moreira, Guimarães, & Joca, 2009). Interestingly, 
deficits in 5-HT signaling have been implicated in a number of neuropsychiatric disorders 
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including anxiety, depression and addiction (see Gingrich & Hen, 2001 for a review).  
Indeed, mice lacking the 5-HT1A receptor display altered emotional states and reactivity 
to environmental cues (Zhuang et al., 1999). Furthermore, 5-HTergic neurotransmission 
through 5-HT1A receptors has been suggested to modulate brain reward processes 
(Harrison & Markou, 2001), and CBD has been shown to inhibit synaptic transmission in 
the hippocampus through 5-HT1A receptors (Ledgerwood, Greenwood, Brett, Pratt, & 
Bushell, 2010). Together, these data suggest that 5-HT1A receptor transmission may be 
required for the accurate processing of emotional and motivational information. It is 
therefore possible that antagonism of 5-HT1A receptors in our study prevented CBD from 
exerting the full range of its psychopharmacological effects. Another possibility is that 5-
HT1A antagonism alone produced an aversive response. However this seems unlikely, as 
rats conditioned with NAD-299 alone did not develop a significant aversion to the 
environment paired with NAD-299 administration. Furthermore, 5-HT1A antagonism is 
not known to produce either appetitive or aversive effects in the CPP paradigm (Risinger 
& Boyce, 2002). 	  
The 5-HT1B receptor is another well-characterized 5-HT receptor subtype and like 
the 5-HT1A receptor, it has been implicated in a number of physiological functions and 
neuropsychiatric disorders (Sari, 2004; Ujike et al., 2011). Furthermore, 5-HT1B receptors 
are highly co-expressed with CB1 receptors in the striatum (Hermann et al., 2002; 
Maroteaux et al., 1992)  suggesting a modulatory role of this receptor in motivational and 
emotional processing. Based on this information, we performed a separate experiment to 
examine whether the rewarding effect of CBD was dependent on 5-HT1B receptor 
signaling. We found that intra-NASh co-administration of CBD with GR-55562, a 5-
HT1B receptor antagonist, was able to block CBD reward memory acquisition (Figure 
3B). Previous studies have found that 5-HT1B receptors are expressed at the nerve 
terminals of GABAergic projection neurons from the nucleus accumbens to the VTA as 
well as DAergic projection neurons from the VTA to the nucleus accumbens (Boschert, 
Amara, Segu, & Hen, 1994; Bruinvels et al., 1994; Maroteaux et al., 1992; Sari, 2004; 
Voigt, Laurie, Seeburg, & Bach, 1991). Additionally, both the NASh and the VTA are 
heavily innervated by serotonergic projections (Lavoie & Parent, 1990; Phelix & 
Broderick, 1995), implicating the serotonergic system as a critical modulator of brain 
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reward pathways. Given that 5-HT1B receptors are inhibitory G-protein coupled receptors, 
it is possible that antagonism of the receptor inhibited the ability of DAergic projection 
neurons from the VTA to be modulated by endogenous 5-HT, thereby raising the overall 
DAergic tone in the NASh. In light of our electrophysiology results (discussed below) 
that indicate that intra-NASh CBD microinfusions result in a decrease in VTA DAergic 
neuronal activity, it is possible that artificially elevating NASh DAergic tone abolishes 
the behaviourally rewarding effect of CBD, which may depend on reduced NASh DA 
originating from the VTA. Together, the results suggest that 5-HT receptor signaling may 
play a crucial role in the rewarding effects of cannabinoids in general, and of CBD in 
particular. 	  	  
2.4.3 CBD reward signals through DA receptor transmission in the NASh 	  
Given that most drugs of abuse elicit increased DA release from the VTA, which 
reinforces drug use behaviours (Adinoff, 2004; Laviolette & Grace, 2006; Margolis, 
Lock, Hjelmstad, & Fields, 2006), we performed separate experiments in order to 
investigate whether the behaviourally rewarding dose of CBD (100ng) was dependent on 
DAergic signaling within the NASh. We found that co-administration of CBD with α-
flupenthixol (100ng, 1.0µg), a DA receptor antagonist, was sufficient to block the 
acquisition of intra-NASh CBD reward memory (Figure 4).   	  
Previous studies have found DA receptor antagonism, using α-flupenthixol, to be 
effective at blocking the acquisition of drug reward memory in the CPP procedure 
(García Horsman & Paredes, 2004). Given that the NASh receives DAergic input from 
the VTA (Ferreira, Del-Fava, Hasue, & Shammah-Lagnado, 2008; Ikemoto, 2007), it is 
highly probable that our intra-NASh DA receptor antagonism prevented increased 
DAergic reward signals from the VTA and thus blocked the acquisition of intra-NASh 
CBD reward memory.   	  	  
2.4.4 CBD modulates intra-VTA DA and GABA neuronal activity	  
In order to elucidate the mechanism of intra-NASh CBD reward in greater detail, we 
performed single unit in vivo electrophysiology experiments in which rats received CBD 
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(100ng/0.5µl) microinfusion into the NASh while we simultaneously recorded single cell 
neuronal activity in the VTA. Given that drugs of abuse elicit phasic DA release from the 
VTA, and that we were successful in blocking intra-NASh CBD reward memory 
acquisition using DA receptor antagonists, we predicted that our behaviourally effective 
dose of CBD (100ng) would elicit a similar increase in DAergic neuronal activity in the 
VTA, providing a mechanism to explain the rewarding effect observed in the CPP 
experiments. Contrary to our hypothesis, the majority of DA cells sampled showed a 
significant decrease in neuronal activity as measured by a decrease in firing frequency 
(Fig. 5C) and a decrease in the number of burst events per minute (Fig. 5D). Of the non-
DA neurons (presumably GABAergic interneurons) sampled, we observed a trend 
towards increased neuronal activity as measured by an increase in firing frequency (Fig. 
6B). Of the subpopulation of neurons exhibiting increased activity, there was a significant 
increase in firing frequency following intra-NASh CBD microinfusion (Fig. 6D). In 
contrast, only a small sample of non-DA neurons showed a decrease in firing frequency 
(Fig. 6A). It is therefore highly probable that the observed decrease in DAergic activity is 
due to the increased inhibitory influence of GABAergic interneurons that modulate the 
activity of DAergic projection neurons to the NASh and other mesocorticolimbic 
structures. 	  
Based on these results, we performed a separate experiment in which rats received 
bilateral cannulae implantations into the NASh as well the VTA, in order to examine 
whether intra-NASh CBD reward was dependent on intra-VTA GABAergic signaling. 
We found that antagonism of both GABAA and GABAB receptors in the VTA was 
sufficient to block the acquisition of intra-NASh CBD reward memory (Figure 7). 
Together with the results from our electrophysiology experiments, these data suggest that 
modulation of DAergic activity by GABAergic interneurons is critical for the acquisition 
of intra-NASh CBD reward memory. These results seem at odds with the results of our 
behavioural experiment using DA antagonists, which suggested that intra-NASh DA 
signaling was necessary for the behavioural expression of CBD reward. It is possible that 
while intra-VTA DAergic neuronal activity was significantly reduced following intra-
NASh CBD microinfusion, the reduced VTA DA signals were still necessary for the 
acquisition of intra-NASh CBD reward memory. Thus, by blocking intra-NASh DA 
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receptors, we had prevented the VTA from being able to send reward-related DA signals 
to the NASh.   	  
Many recent research efforts have focused on elucidating the mechanism by 
which CBD may exert its antipsychotic properties (Mechoulam et al., 2007). One recent 
study (Leweke et al., 2012) suggests that the ability of CBD to prevent the degradation of 
the endocannabinoid anandamide may be at least partially responsible for CBD’s 
antipsychotic efficacy.  In the present study, we present evidence that CBD can modulate 
mesolimbic DA activity by decreasing DAergic activity in the VTA. Given that 
mesolimbic DA hyperactivity has been implicated as a major etiological factor in a 
number of neuropsychiatric disorders including addiction and schizophrenia (Laviolette 
& Grace, 2006; Mehler-Wex, Riederer, & Gerlach, 2006), these data represent another 
possible pharmacological mechanism that may be responsible for CBD’s antipsychotic 
actions.	  
 
2.5 Summary	  
This study presents the first evidence for hedonic properties of CBD, long believed to be 
devoid of reinforcing effects. Our results support past research showing that cannabinoids 
have a diverse range of pharmacological effects including interactions with the 
serotonergic, DAergic and GABAergic neurotransmitter systems. Our electrophysiology 
results lend further credence to the notion that cannabinoids are unique in the world of 
abused drugs as CBD actually drives inhibition of VTA DAergic transmission. Future 
studies should examine the electrophysiological changes induced by 5-HT1A receptor 
antagonism on VTA neuronal activity in order to determine the mechanism that switches 
CBD’s motivational valence from rewarding to aversive.  
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Chapter 3. Cannabidiol and Δ9-tetrahydrocannbinol differentially 
modulate the acquisition of an associative fear memory in the 
nucleus accumbens shell	  	  
3.1 Introduction   	  
Dysfunction in emotional and motivational information processing is a hallmark of the 
cognitive deficits observed in schizophrenia. This can manifest as abnormal social 
cognition and impaired emotional expression, and may lead to aberrant salience 
attribution to what would normally be insignificant sensory experiences or events. In the 
extreme, such attribution may lead to psychotic ideation and persistent maladaptive 
behaviours (Laviolette & Grace, 2006). Cannabinoids can produce similarly profound 
effects on emotional information processing and sensory perception (D’Souza et al., 
2005) by acting on centralized CB1 receptors. Acute cannabinoid exposure can lead to 
paranoid thought processes, anxiety and agitation even among healthy individuals and 
may precipitate episodes of psychosis in individuals predisposed to psychotic disorders 
(Bhattacharyya et al., 2012). Several neural structures comprise the emotional processing 
circuitry, collectively referred to as the mesocorticolimbic system. These areas contain 
high levels of dopamine (DA) and CB1 receptors, which are critical in emotional salience 
processing. Furthermore, both of these neurotransmitter systems have been implicated in 
the etiology and neuropathological profile of schizophrenia (Eggan, Hashimoto, & Lewis, 
2008; Lauzon, Bishop, & Laviolette, 2009; Laviolette & Grace, 2006; Scatton & Sanger, 
2000), and structural and functional abnormalities in mesocorticolimbic structures have 
been reported in patients with schizophrenia (Burns et al., 2003; Crespo-Facorro et al., 
2001; Taylor, Liberzon, Decker, & Koeppe, 2002). Abnormalities in endocannabinoid 
signaling in particular have been implicated in the aberrant emotional processing 
observed in psychosis (Dalton, Long, Weickert, & Zavitsanou, 2011; Hall, Degenhardt, & 
Teesson, 2004), and there is also a growing body of evidence which supports the link 
between excessive marijuana exposure, especially during adolescence, and an increased 
risk of developing schizophrenia-related psychoses in later adulthood (Bossong & 
Niesink, 2010; Semple, 2005; Smit et al., 2004).  
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However, marijuana smoke represents a complex mixture of chemical 
components, possessing dissociable psychoactive and pharmacological properties 
(ElSohly & Slade, 2005; Radwan et al., 2009). While Δ9-THC may precipitate, or even 
exacerbate psychotic symptoms, CBD has been shown to have antipsychotic and 
anxiolytic properties (Bhattacharyya, et al., 2009b).  
The goal of the current study was to investigate the effects of CBD and Δ9-THC 
on the encoding of emotionally salient information using an olfactory fear conditioning 
procedure.  Evidence from our laboratory has shown that activation of CB1 receptors in 
discrete mesocorticolimbic regions can significantly potentiate the salience of an 
emotional memory, while blockade of CB1 receptor transmission blocks emotional 
associative learning in this paradigm (Lauzon et al., 2009; Laviolette, 2006; Tan et al., 
2010).  However, the effects of distinct, marijuana-specific, compounds on the encoding 
of emotionally salient associative memories are not well understood. In the current study, 
we performed several pharmacological behavioural experiments in which rats received 
microinfusions of CBD or Δ9-THC into the shell subdivision of the nucleus accumbens 
(NASh), a structure that is sensitive to cannabinoids (Mahler et al., 2007; Zangen et al., 
2006) and plays a crucial role in emotional processing and motivated behaviour (Di 
Chiara, 2002; Di Chiara et al., 2004). We report that Δ9-THC microinfusions potentiated 
the acquisition of a subthreshold fear memory through a DA-dependent mechanism. In 
contrast, CBD microinfusions were effective at blocking the acquisition of a 
suprathreshold fear memory through a 5-HT1A-dependent mechanism. CBD was also 
effective at abolishing Δ9-THC-induced potentiation of a subthreshold fear memory. 
Implications for neuropsychiatric disorders are discussed.  
3.2 Materials and Methods 
3.2.1 Animals and Surgery 	  
Male Sprague Dawley rats (300-350g) were obtained from Charles River Laboratories 
(Quebec, CAN). Rats were anesthetized with an intraperitoneal (i.p.) injection of a 
ketamine (80mg/ml)-xylazine (6mg/kg) mixture and meloxicam (1.0 mg/kg; s.c.) was 
administered preoperatively in order to reduce pain and post-surgical inflammation. 
Following an assessment of anesthetic depth, rats were immobilized using a Kopf 
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stereotaxic device. Using sterile technique, an incision was made to expose the skull.  
Guide cannulae (22-gauge) were implanted bilaterally into the NASh using flat skull 
stereotaxic coordinates as follows (12o angle, in mm from bregma): anteroposterior (AP) 
+ 1.8, lateral (LAT) ± 2.6, ventral (V) -7.4 from the dural surface. All stereotaxic 
coordinates were based upon the atlas of Paxinos and Watson (1996). Cannulae were 
secured to the skull using four small jeweler’s screws and dental acrylic. Dust-caps were 
used to ensure the patency of the cannulae.  All procedures were performed in accordance 
with the Canadian Council on Animal Care (CCAC) and were approved by Western 
University’s Council on Animal Care. 
 
3.2.2 Post-Surgery SOP 	  
Rats were injected subcutaneously with 3 – 10 mL of physiological saline in order to 
prevent dehydration. Rats recovered in a clean home cage filled with wood shavings and 
warmed under a heat lamp. Behaviour was monitored until recovery from the anesthetics 
and sternal recumbency attained.  A maintenance dose of meloxicam (1.0 mg/kg) was 
administered (s.c.) 24 hours post-surgery in order to reduce pain and inflammation. 
Following at least one week of recovery, rats were then tested in behaviorual paradigms.  
 
3.2.3 Olfactory fear conditioning 	  
All rats were conditioned using a fully counterbalanced olfactory fear conditioning 
procedure, as described previously (Lauzon et al., 2009; Laviolette, 2005). Rats were 
taken from their home cages and received sham microinfusions into the NASh before 
being habituated for 30 min to the conditioning apparatus, a ventilated chamber with a 
metallic electric grid floor. Conditioning took place 24 hrs later in one of two visually 
distinct environments. The first environment was a 30” x 30” Plexiglas box with black 
stripes on a white background and a metallic electric grid floor (shock environment A). 
The second environment was a 30” x 30” Plexiglas box with black dots on a white 
background and a metallic grid floor (shock environment B).  Testing occurred 24 hrs 
later in one of two alternate environments in which rats did not receive electric foot 
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shock. The first environment was a 30” x 30” Plexiglas box with black stripes on a white 
background and a grey Plexiglas floor (test environment A), while the second 
environment had black dots on a white background with a gray Plexiglas floor (test 
environment B). This fear conditioning procedure is context independent as rats are 
conditioned and tested in distinct environments, with only olfactory conditioning cues 
being consistent across the experimental procedure. On day 1 (habituation), rats were 
habituated to a random combination of shock environment A or B and test environment A 
or B for 30 min in each environment. On day 2 (conditioning) rats were placed in their 
previously assigned shock environment. During conditioning, one of two distinct odours 
(almond or peppermint) were presented for 19s, followed by a 1s footshock (CS+) of 
either 0.4 mA or 0.8 mA. The alternate odour is presented 120s later for a duration of 20s 
in the absence of a footshock (CS-). This procedure is repeated five times. By modulating 
the intensity of foot shock administered (either a subthreshold foot shock of 0.4 mA that 
normally does not produce an associative fear memory, or a suprathreshold foot shock of 
0.8 mA that produces robust fear memory), we can examine how specific 
pharmacological manipulations can either potentiate normally non-salient emotional 
memory events, or block the encoding of highly salient emotional memory events 
(Laviolette, 2006).   
Testing occurred 24hrs after conditioning, when rats were placed in their previously 
assigned test environment. Rats were permitted to explore the testing apparatus for 1 min 
before odour presentation, during which time baseline levels of freezing and exploratory 
behaviour were recorded. Rats were then exposed to the CS+ and CS- odours for 5 
minutes in a counterbalanced fashion and the percentage of time the rat spent “freezing”, 
a measure of conditioned fear, was recorded. Freezing was defined as complete 
immobility with the exception of respiratory-related movements.  
3.2.4 Drug administration   	  
The broad-spectrum DA receptor antagonist, α-flupenthixol, the highly specific 5-HT1B 
receptor antagonist, GR-55562, the GABAA antagonist, bicuculline methiodide, and the 
GABAB antagonist, hydroxysaclofen, were dissolved in physiological saline (pH adjusted 
to 7.4). The 5-HT1A receptor antagonist, NAD-299 hydrochloride, and CBD were 
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dissolved in dimethyl sulfoxide (DMSO, Fisher Scientific). Δ9-THC was dissolved in 
100% ethanol and cremophor EL (Sigma-Aldrich). Ethanol was removed using nitrogen 
stream evaporation and the final solution was diluted with filtered saline.  For NASh 
microinfusions, stainless steel guide cannulae (22-gauge) were implanted bilaterally into 
the NASh through a 28-gauge microinfusion injector (Plastics One). Bilateral 
microinfusions were performed over 1 min through a Hamilton microsyringe. In order to 
ensure the diffusion of the drug away from the injector tip, the internal cannulae were left 
in place for an additional minute. All drugs were purchased from Tocris Biosciences.  
 
3.2.5 Histology 	  
Following completion of experiments, rats were transcardially perfused, brains were 
extracted and stored in a specimen vial containing formalin with 25% sucrose solution for 
at least 24hrs. The region of the projected cannulae placements were cut into 40 µm 
coronal sections, mounted, and stained using cresyl violet to allow for histological 
examination of the injection site. The majority of NASh placements were localized within 
the region of the shell of the nucleus accumbens. Rats found to have injectors situated 
outside the anatomical boundaries of the NASh were excluded from experimental 
analysis.   
3.2.6 Data analysis  	  
Data were analyzed with a mixed-model ANOVA with a between subjects factor of 
treatment, and a within subjects factor of stimulus, followed by paired-samples t-tests. 
3.3 Results	  
3.3.1 Histological analysis 	  
Histological analysis revealed microinfusion injector cannulae placements to be 
bilaterally localized within the anatomical boundaries of the shell subdivision of the 
nucleus accumbens, according to the Rat Brain Atlas (Paxinos & Watson, 1996). Figure 
8A presents a microphotograph displaying a typical injector placement within the NASh. 
Figure 8B displays a schematic illustration showing representative intra-NASh bilateral 
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cannuale placements along the rostral-caudal axis of the nucleus accumbens. Rats with 
cannulae placements located outside of the NASh were removed from data analysis.      
	  
Figure 8. Histological analysis of intra-NASh microinjection sites. A, 
Microphotograph of a representative injector placement within the shell subdivision (Sh) 
of the NAcc. Injectors located in the core (Co) were removed from analyses. B, 
Schematic representation of select intra-NASh injector locations; • = 100ng CBD group, 
♦ = 100ng Δ9-THC group. 	  
 
3.3.2 Intra-NASh Δ9-THC microinfusion potentiates the formation of a 
subthreshold fear memory through a DA-dependent mechanism 	  
In order to test the hypothesis that intra-NASh Δ9-THC would potentiate the formation of 
a subthreshold fear memory, rats received microinfusions of intra-NASh Δ9-THC, 50ng 
(n = 8) or 100ng (n = 7), prior to olfactory fear conditioning with a subthreshold (0.4mA) 
footshock. In follow-up experiments, animals received 100ng Δ9-THC co-administered 
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with either 100ng (n = 5) or 1.0µg (n = 5) of the DA receptor antagonist α-flupenthixol, 
or 100ng (n = 5) of the 5-HT1A receptor antagonist NAD-299 (Figure 9). 
A mixed-model ANOVA revealed that the main effect of treatment was 
significant, F (5, 29) = 4.13, p = .006, indicating that the mean percentage of time spent 
freezing was significantly different between treatment groups. The main effect of 
stimulus was significant, F (1, 29) = 50.07, p = .000, indicating a significant difference in 
the mean percentage of time rats spent freezing in response to the CS+ and CS- odours. 
Finally, the interaction between stimulus and treatment was significant, F (5, 29) = 8.90, 
p = .000, suggesting that the mean percentage of time spent freezing to the CS+ and CS- 
odours significantly differs as a function of treatment group. Follow-up paired samples t-
tests revealed that rats receiving vehicle microinfusions did not spend a significantly 
higher percentage of time freezing to the CS+ odour (M = 10.36, SD = 1.69) than to the 
CS- odour (M = 9.83, SD = 1.81), t (5) = -0.386, p = .72. In contrast, intra-NASh Δ9-THC 
microinfusions potentiated the acquisition of the subthreshold associative fear memory. 
Rats receiving Δ9-THC at doses of 50ng (MCS- = 12.88, SDCS- = 4.06; MCS+ = 30.07, 
SDCS+ = 4.54), t (7) = -6.631, p = .000, and 100ng (MCS- = 19.85, SDCS- = 3.32; MCS+ = 
39.48, SDCS+ = 5.19), t (6) = -3.493, p = .013, spent significantly more time freezing to the 
CS+ odour as compared to the CS- odour.  The effect of Δ9-THC was abolished when 
rats were co-administered with the DA receptor antagonist α-flupenthixol. Rats receiving 
concurrent α-flupenthixol at doses of 100ng (MCS- = 20.86, SDCS- = 5.64; MCS+ = 22.74, 
SDCS+ = 6.59), t (4) = -.797, p = .47, and 1.0µg (MCS- = 12.7973, SDCS- = 2.04076; MCS+ = 
12.4313, SDCS+ = 1.69558), t (4) = .371, p = .73, did not spend significantly more time 
freezing to the CS+ odour as compared to the CS- odour. The effect of Δ9-THC was not 
blocked by the 5-HT1A receptor antagonist NAD-299. Rats co-infused with 100ng NAD-
299 spent significantly more time freezing to the CS+ odour (M = 40.75, SD = 5.76) as 
compared to the CS- odour (M = 15.03, SD = 4.31), t (3) = -4.822, p = .017.  
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Figure 9. Mean (±SEM) percentage of time spent freezing to the CS+ and CS- for 
rats microinfused with intra-NASh Δ9-THC. Intra-NASh Δ9-THC potentiates the 
formation of an associative fear memory to a normally non-salient, subthreshold (0.4mA) 
foot shock. Co-administration of the DA receptor antagonist α-flupenthixol blocks Δ9-
THC-induced fear memory potentiation. In contrast, co-administration of the 5-HT1A 
receptor antagonist NAD-299 does not does not block Δ9-THC-induced fear memory 
potentiation. * p < .05. 	  
3.3.3 Intra-NASh CBD microinfusion blocks the formation of a suprathreshold fear 
memory through a 5-HT1A-dependent mechanism 	  
In order to test the hypothesis that intra-NASh CBD would block the formation of a 
suprathreshold fear memory, rats received microinfusions of intra-NASh CBD, 10ng (n = 
8) or 100ng (n = 8), prior to olfactory fear conditioning with a suprathreshold (0.8mA) 
footshock. In follow-up experiments, animals received 100ng CBD co-administered with 
either 10ng (n = 7) or 100ng (n = 7) of the 5-HT1A receptor antagonist NAD-299, 100ng 
(n = 7) of the 5-HT1B receptor antagonist GR-55562, or 100ng (n = 4) of the DA receptor 
antagonist α-flupenthixol (Figure 10).  
A mixed-model ANOVA revealed that the main effect of treatment was not 
significant, F (6, 41) = 1.61, p = .169, indicating that the mean percentage of time spent 
freezing was not significantly different between treatment groups. The main effect of 
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stimulus was significant, F (1, 41) = 39.76, p = .000, indicating a significant difference in 
the mean percentage of time rats spent freezing in response to the CS+ and CS- odours. 
Finally, the interaction between stimulus and treatment was significant, F (6, 41) = 4.25, 
p = .002, suggesting that the mean percentage of time spent freezing to the CS+ and CS- 
odours significantly differs as a function of treatment group. Follow-up paired samples t-
tests revealed that rats receiving vehicle microinfusions spent a significantly higher 
percentage of time freezing to the CS+ odour (M = 59.95, SD = 27.06) than to the CS- 
odour (M = 41.50, SD = 25.77), t (6) = -2.49, p = .047. In contrast, intra-NASh CBD 
microinfusions blocked the acquisition of the suprathreshold associative fear memory. 
Rats receiving CBD at doses of 10ng (MCS- = 16.55, SDCS- = 6.46; MCS+ = 22.60, SDCS+ = 
13.31), t (7) = -2.11, p = .073, and 100ng (MCS- = 30.81, SDCS- = 24.37; MCS+ = 43.61, 
SDCS+ = 27.10), t (7) = -2.18, p = .065, did not spend significantly more time freezing to 
the CS+ odour as compared to the CS- odour.  The effect of CBD was abolished when 
rats were co-administered with the 5-HT1A receptor antagonist NAD-299. Rats receiving 
concurrent NAD-299 at doses of 10ng (MCS- = 23.43, SDCS- = 15.75; MCS+ = 56.98, SDCS+ 
= 35.15), t (6) = -3.81, p = .009, and 100ng (MCS- = 29.52, SDCS- = 10.17; MCS+ = 60.43, 
SDCS+ = 21.48), t (6) = -4.65, p = .004, spent significantly more time freezing to the CS+ 
odour as compared to the CS- odour. The effect of CBD was not blocked by the 5-HT1B 
receptor antagonist GR-55562. Rats co-infused with 100ng GR-55562 did not spend 
significantly more time freezing to the CS+ odour (M = 44.13, SD = 32.61) as compared 
to the CS- odour (M = 38.47, SD = 30.79), t (6) = -1.63, p = .154. Additionally, the effect 
of CBD was not blocked by the DA receptor antagonist α-flupenthixol. Rats co-infused 
with 100ng α-flupenthixol did not spend significantly more time freezing to the CS+ 
odour (M = 27.44, SD = 12.07) as compared to the CS- odour (M = 29.36, SD = 18.07), t 
(3) = 0.335, p = .759. 
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Figure 10. Mean (±SEM) percentage of time spent freezing to the CS+ and CS- for 
rats microinfused with intra-NASh CBD. Intra-NASh CBD prevents the formation of 
an associative fear memory to a normally highly salient, suprathreshold (0.8mA) foot 
shock. Co-administration of the 5-HT1A receptor antagonist NAD-299 rescues the 
acquisition of suprathreshold fear memory. In contrast, co-administration of the 5-HT1B 
receptor antagonist GR-55562 or the DA receptor antagonist α-flupenthixol does not does 
not rescue the acquisition of this fear memory. * p < .05 	  
3.3.4 Intra-NASh CBD microinfusion blocks Δ9-THC-induced potentiation of a 
subthreshold fear memory   	  
Based on emerging evidence, which suggests that CBD antagonizes many of the 
behavioural and pharmacological effects of Δ9-THC, we performed a separate 
experiment in which rats received intra-NASh microinfusions of 100ng CBD in 
combination with 100ng Δ9-THC prior to fear conditioning with a subthreshold 
footshock in order to examine whether CBD was able to block Δ9-THC-induced 
potentiation of a subthreshold fear memory (Figure 11).  A paired samples t-test revealed 
that 100ng CBD was able to block the potentiation effect of 100ng Δ9-THC, t (7) = -0.67, 
p  = .53. Rats did not spend significantly more time freezing to the CS+ odour (M = 
32.59, SD = 26.03) as compared to the CS- odour (M = 29.83, SD = 28.23). These data 
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are in line with a wealth of evidence that supports a modulatory role of CBD over the 
psychotomimetic effects of Δ9-THC.  
 
	  
Figure 11. Mean (±SEM) percentage of time spent freezing to the CS+ and CS- for 
rats microinfused with intra-NASh CBD and Δ9-THC. Intra-NASh 100ng Δ9-THC 
potentiates the formation of an associative emotional memory to a normally non- salient, 
subthreshold (0.4mA) foot shock. This effect is abolished by co- administration with 
100ng CBD, which blocks Δ9-THC-induced potentiation of a subthreshold fear memory. 
 
3.4 Discussion 	  
Dysfunctions in accurately processing the emotional significance of incoming sensory 
stimuli and coordinating normative cognition and appropriate behavioural responses are 
pervasive deficits in individuals suffering from schizophrenia (Kohler & Martin, 2006). 
This is suggestive of dysfunctions in the mesocorticolimbic system, the underlying 
neurocircuitry that regulates emotional information processing (Grace, 2000). Indeed, 
imaging studies of schizophrenia patients reveal severe structural and functional 
abnormalities in various mesocorticolimbic structures (Ellison-Wright & Bullmore, 
2009). Furthermore, evidence suggests a positive correlation between the severity of 
psychotic symptoms and the degree of impairment in emotional processing (Crespo-
Facorro et al., 2001). The nucleus accumbens (NAcc) plays a central role in emotional 
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processing as it sends and receives projections to a number of other mesocorticolimbic 
structures (Heimer, Zahm, Churchill, Kalivas, & Wohltmann, 1991), integrates 
information from these regions and produces goal-directed behavioural outputs (Goto & 
Grace, 2008). In particular, the shell subdivision of the nucleus accumbens (NASh) is a 
structure that has been implicated in the etiology of schizophrenia, and has been 
suggested as a novel and efficacious target for antipsychotic medications (Deutch, Lee, & 
Iadarola, 1992).  
Although the precise mechanisms underlying cannabis-induce psychosis remain 
unknown, evidence is mounting to suggest alterations in cortical and limbic emotional 
processing regions as key factors. Previous studies have found that Δ9-THC induces 
elevations in DAergic tone in the VTA (French et al., 1997) and the NAcc (Gardner et al., 
1988; Oleson & Cheer, 2012) and can induce transient psychotic symptoms following 
even acute exposure (Bhattacharyya et al., 2012). Furthermore, dysfunctions in cortical 
endocannabinoid signaling have been implicated in the abberant emotional experiences in 
patients with paranoid schizophrenia (Dalton et al., 2011), and structural alternations 
have been observed in the NAcc and amygdala in regular cannabis users (Gilman et al., 
2014). Taken together, these data suggest that cannabinoid action at structures involved 
in emotional processing may represent a potential mechanism that contributes to the 
emotional disturbances observed in cannabis-induced, schizophrenia-related psychosis. 
Our previous work has shown that modulation of CB1 transmission in the BLA—
mPFC pathway can mediate the emotional valence of an associative fear memory in an 
olfactory fear-conditioning paradigm. Activation of CB1 receptors in these areas results 
in the potentiation of normally non-salient emotional associative memories, while CB1 
receptor blockade prevents the formation of conditioned fear memories (Laviolette & 
Grace, 2006; Tan et al., 2011). We report here that CBD and Δ9-THC can similarly 
modulate emotional memory formation in the NASh, and provide further insight into how 
cannabis-specific cannabinoids may elicit disturbances in emotional information 
processing.  
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3.4.1 Intra-NASh Δ9-THC potentiates the formation of a subthreshold fear memory 
through a DA-dependent mechanism  	  
Given our previous findings that activation of CB1 receptors can potentiate non-salient 
emotional experiences in discrete mesocorticolimbic structures, we performed a series of 
behavioural experiments in which rats received microinfusions of Δ9-THC into the NASh 
prior to fear conditioning with a subthreshold (0.4mA) footshock. Our analyses revealed 
that while rats treated with vehicle microinfusions did not form a significant fear memory 
to the odour paired with a non-salient subthreshold footshock, those treated with Δ9-THC 
(50, 100ng) demonstrated a potentiation of associative fear memory formation as 
measured by a significant increase in the percentage of time spent freezing in response to 
the shock-paired odour (CS+). Based on evidence showing that Δ9-THC administration 
increases mesolimbic DA levels (Oleson & Cheer, 2012), we performed follow-up 
experiments in which we challenged our highest behaviourally effective dose of Δ9-THC 
(100ng) with co-administration of α-flupenthixol (100ng, 1.0µg), a DA receptor 
antagonist. Our results revealed that antagonism of DA receptors in the NASh was 
sufficient to block Δ9-THC-induced potentiation of a subthreshold footshock. A final 
follow-up experiment in which Δ9-THC was challenged with NAD-299, a 5-HT1A 
antagonist, revealed that 5-HT1A signaling was not necessary for Δ9-THC-induced 
potentiation of a subthreshold footshock (Figure 9).  
These data suggest that the disturbances in emotional processing induced by Δ9-
THC are in part dependent on DA signaling substrates in the NASh, and may provide a 
mechanism to explain the propsychotic effects of Δ9-THC and other potent cannabinoids. 
Abnormalities in endocannabinoid and DAergic signaling have been implicated in the 
aberrant emotional processing observed in schizophrenia (Dalton et al., 2011; Hall et al., 
2004; Moore, West, & Grace, 1999), and previous research has shown that the 
endocannabinoid and DAergic systems functionally interact such that cortical CB1 
transmission modulates subcortical mesolimbic DA activity (Bossong & Niesink, 2010; 
Diana et al., 1998). Indeed, cannabis use is known to induce alterations in sensory 
perception: environmental stimuli may become more salient and their emotional valence 
may be amplified (Green et al., 2003; Wachtel et al., 2002). These effects share many 
similarities with the cognitive, social and emotional disturbances observed in 
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schizophrenia, and CB1 receptor activation has been shown to exacerbate psychotic and 
cognitive symptoms in schizophrenia patients (Bossong, Jansma, Bhattacharyya, & 
Ramsey, 2014; D’Souza et al., 2005).   
In the current study, the aberrant emotional processing induced by acute Δ9-THC 
administration was abolished with concurrent administration of α-flupenthixol, a DA 
receptor antagonist and potent antipsychotic. Previous research implicates disruptions in 
DAergic signaling in the NAcc as an etiological factor in schizophrenia (Goto & Grace, 
2008; Grace, 2000). Taken together, this suggests that intra-NASh Δ9-THC may have 
induced alterations in accumbal DAergic tone that manifests at the behavioural level as 
distortions in emotional information processing (Pezze & Feldon, 2004). Indeed, Δ9-
THC, like all known drugs of abuse, induces DA release from the VTA to the NAcc 
(Bossong et al., 2008; French et al., 1997; Gardner, 2005; Tanda & Goldberg, 2003), 
presumably by inhibiting GABAergic interneuron activity in the VTA (Szabo, Siemes, & 
Wallmichrath, 2002). 
The NAcc modulates mesolimbic DA levels by sending direct and indirect 
GABAergic projections to the ventral tegmental area (VTA) via medium spiny neurons 
(MSN; Xia et al., 2011). The VTA in turn sends DAergic projections back to the NAcc 
and other mesocorticolimbic structures ( Ferreira et al., 2008; Grace et al., 2007; Heimer 
et al., 1991). CB1 receptors are highly expressed on presynaptic GABAergic interneurons 
in limbic structures (Elphick & Egertova, 2001; Pertwee & Ross, 2002; Rodriguez, 
Mackie, & Pickel, 2001). Thus it is possible that Δ9-THC’s activation of CB1 receptors 
located on presyanptic GABAergic interneurons in the NASh disinhibits MSN projection 
neurons to the VTA. This in turn would inhibit VTA GABAergic interneurons, hence 
releasing VTA DAergic projection neurons from tonic inhibition and, thus, exciting DA 
release from the VTA to the NAcc (see Figure 12). This model, in combination with our 
behavioural results, is in line with evidence suggesting that increased DA release from 
the VTA to the NASh potentiates behavioural responding to conditioned aversive stimuli 
(Pezze & Feldon, 2004), and provides a potential mechanism to explain the propsychotic 
properties of Δ9-THC.   
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Figure 12. Proposed model for the pharmacological action of Δ9-THC in the NAcc-
VTA pathway.  DA: dopamine; MSN: medium spiny neuron; NAcc: nucleus 
accumbens; VTA: ventral tegmental area. 	  
3.4.2 Intra-NASh CBD blocks the formation of a suprathreshold fear memory 
through a 5-HT1A-dependent mechanism  	  
Given CBD’s antagonistic action at CB1 receptors, we performed behavioural 
experiments in which rats received intra-NASh microinfusions of CBD (10, 100ng) prior 
to conditioning with a suprathreshold footshock in order to examine whether CBD was 
effective at blocking the acquisition of an associative fear memory similar to what was 
observed with synthetic CB1 receptor antagonists in previous studies (Laviolette & 
Grace, 2006; Tan et al., 2011). Our results indicate that CBD was effective at blocking 
the acquisition of a highly salient suprathreshold fear memory. This effect was dependent 
on 5-HT1A receptor signaling, however was independent of 5-HT1B and DA receptor 
signaling (Figure 10).  
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Numerous studies have shown CBD to be effective at attenuating the acquisition 
and expression (Gomes et al., 2012; Lemos, Resstel, & Guimarães, 2010), and facilitating 
the extinction (Bitencourt, Pamplona, & Takahashi, 2008), of conditioned fear. Although 
the current results indicate that CBD’s effects in the NASh depend on 5-HT1A receptor 
signaling; it is not possible to rule out alternative pharmacological mechanisms.   Recent 
studies reveal CBD to have a wide range of pharmacological actions, which may explain 
its profound effect in fear conditioning paradigms including: antagonism of CB1 
receptors (Thomas et al., 2009), agonistic action at 5-HT1A receptors (Russo et al., 2005), 
and inhibition of FAAH, the enzyme which catalyzes the degradation of AEA one of the 
major endocannabinoids and endogenous ligands of the CB1 receptor (Bisogno et al., 
2001). 
Interestingly, CB1 receptor transmission, 5-HT1A receptor signaling and AEA 
tone have all been implicated as playing critical roles in the acquisition, expression and 
extinction of conditioned fear responses. For example, CB1 receptor antagonism has been 
shown to block the acquisition of a highly salient associative fear memory (Laviolette, 
2006; Tan et al., 2011), and mice lacking the CB1 receptor show impairments in 
extinction learning in associative fear paradigms (Cannich et al., 2004; Marsicano et al., 
2002). Agonists of the 5-HT1A receptor facilitate fear extinction in animals conditioned to 
aversive stimuli (Saito et al., 2012), and mice lacking the 5-HT1A receptor show increased 
fear responses to contextual fear cues (Klemenhagen, Gordon, David, Hen, & Gross, 
2005). Furthermore, a study by Gomes et al. (2012) demonstrated that microinfusions of 
CBD into the bed nucleus of the stria terminalis  attenuates  behavioural expression in a 
fear conditioning paradigm and that this effect is blocked with 5-HT1A receptor 
antagonism. Other studies found that inhibition of AEA reuptake was effective at 
facilitating the extinction of conditioned fear (Bitencourt et al., 2008; Chhatwal, Davis, 
Maguschak, & Ressler, 2004).  Our results are thus in line with a growing body of 
research demonstrating the diverse pharmacological and behavioural effects of CBD in an 
associative fear conditioning paradigm. These findings are particularly notable, however, 
as we have extended these findings to a discrete neuroanatomical structure, specifically 
the shell subdivision of the NAcc.  
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From a mechanistic perspective, it is possible that CBD exerts its 
neuropsychological effects in precisely the opposite manner of Δ9-THC. While Δ9-THC 
presumably activates intra-NASh CB1 receptors on presynaptic GABAergic interneurons, 
ultimately resulting in increased VTA DAergic output to the NASh, CBD likely blocks 
intra-NASh presynaptic CB1 receptors on GABAergic interneurons, allowing   MSN 
GABAergic projection neurons to be inhibited. This frees intra-VTA GABAergic 
interneurons from tonic inhibition allowing them in turn to inhibit DAergic projection 
neurons back to the NASh and thus decreasing DAergic tone in the NASh (Figure 13). 
This theoretical model is in line with the results from our electrophysiology studies 
discussed earlier (see section 2.4.4).    
CBD’s modulation of the formation and recall of emotionally salient associative 
memories has interesting implications for its use as an effective pharmacotherapy in 
various neuropsychiatric disorders such as addiction and post-traumatic stress disorder 
(PTSD). These disorders are characterized by recurrent, persistent and intrusive recall of 
memories associated with emotionally salient experiences, which infringes upon normal 
cognition. These may be aversive traumatic experiences as in PTSD, or drug-related 
reward memories in the case of addiction, in which the individual is unable to suppress 
the spontaneous recall of memories associated with those experiences (Rothbaum & 
Davis, 2003). Indeed, recent studies have shown CBD to be effective at attenuating 
PTSD-like symptoms and facilitate extinction of aversive associative memories in fear 
conditioning paradigms, which model many features of the disorder (Bitencourt et al., 
2008; Campos et al., 2012; Lemos et al., 2010; Resstel, Joca, Moreira, Corrêa, & 
Guimarães, 2006). Furthermore, individuals suffering from PTSD have been shown to 
have reductions in circulating endocannabinoid levels (Hill et al., 2013) and that 
treatment with CBD helps to alleviate many symptoms of PTSD (Greer, Grob, & 
Halberstadt, 2014; Passie, Emrich, Karst, Brandt, & Halpern, 2012). This effect is 
presumably due to CBD’s ability to raise endocannabinoid tone by inhibiting the 
degradation of AEA.  CBD administration has also been found to be effective at 
attenuating opioid-seeking behaviour in rats trained to self-administer heroin, and even 
normalized mesolimbic neuronal disturbances induced by chronic heroin administration 
(Ren, Whittard, Higuera-Matas, Morris, & Hurd, 2009). Emerging basic and clinical 
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evidence suggests that CBD and other cannabinoids represent potentially effective 
therapeutic compounds in the treatment of PTSD (Greer et al., 2014; Neumeister, 2012; 
Passie et al., 2012) and various other neuropsychiatric disorders such as schizophrenia, 
anxiety and depression (Mechoulam et al., 2007; Schubart et al., 2013; Scuderi et al., 
2009; Zuardi et al., 2006).  
 
 
	  
Figure 13. Proposed model for the pharmacological action of CBD in the NAcc-VTA 
pathway.  DA: dopamine; MSN: medium spiny neuron; NAcc: nucleus accumbens; 
VTA: ventral tegmental area. 	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3.4.3 Intra-NASh CBD blocks Δ9-THC-induced potentiation of a subthreshold fear 
memory  	  
Numerous lines of basic and clinical evidence show a dissociation between CBD and Δ9-
THC at both the pharmacological and behavioural levels (Bhattacharyya et al., 2009b; 
Fusar-Poli et al., 2009; Pertwee, 2008; Petitet et al., 1998; Vann et al., 2008). These 
effects may be attributable to Δ9-THC and CBD’s differential pharmacological action at 
CB1 receptors. Given the opposing pharmacological and behaviorual properties of Δ9-
THC and CBD, and the substantial evidence which suggests that CBD attenuates many of 
the psychopharmacological actions of Δ9-THC, we completed a separate study in which 
rats received microinfusion of intra-NASh Δ9-THC (100ng) in combination with CBD 
(100ng) prior to being conditioned with a subthreshold foot shock, in order to determine 
if CBD was effective at blocking Δ9-THC-induced potentiation of fear memory. The 
infusion doses were chosen based on our maximally effective doses from each of the Δ9-
THC and CBD experiments.  
Our results (Figure. 11) reveal that co-administration of CBD is sufficient to block 
fear memory potentiation induced by Δ9-THC administration.  These results are in line 
with recent evidence demonstrating that CBD is effective at antagonizing many of the 
psychopharmacological effects of Δ9-THC. In humans, pre-treatment with CBD has been 
shown to be effective in attenuating the appetitive (Morgan, Freeman, Schafer, & Curran, 
2010),  propsychotic (Bhattacharyya, Fusar-Poli, et al., 2009a) and anxiogenic (Englund 
et al., 2012; Zuardi, Shirakawa, Finkelfarb, & Karniol, 1982) effects induced by Δ9-THC 
administration. In animals, there is evidence that CBD can modulate the heterogenous 
reinforcing properties of Δ9-THC by attenuating both its aversive and rewarding effects 
(Vann et al., 2008).  
Given the results from our electrophysiology experiments with CBD 
microinfusions, its seems likely that CBD antagonized the excitation of VTA DAergic 
neurons induced by Δ9-THC microinfusion (French et al., 1997), and therefore abolished 
its potentiation of a non-salient subthreshold stimulus.   
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3.5 Summary	  	  
This study presents evidence for the dissociable and opposite effects of Δ9-THC and 
CBD on emotional memory acquisition. Our results support the diverse pharmacological 
properties of plant cannabinoids as well as their pharmacokinetic interactions, which have 
been established by recent research efforts, and findings presented from complimentary 
studies from our laboratory (see Chapter 2). Future studies should examine the 
electrophysiological changes induced by intra-NASh Δ9-THC and CBD in emotional 
regulation structures (e.g., VTA, amygdala) during olfactory fear conditioning in 
anesthetized rats (as described in Laviolette, 2005), in order to more fully elucidate the 
neurophsyiological mechanisms that underlie cannabinoid-mediated effects on emotional 
information processing.  
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Chapter 4. General Conclusions and Future Directions  
 
The work presented in this thesis represents one of the first systematic evaluations of 
phytocannabinoid effects in discrete neural substrates during emotional learning 
paradigms and describes novel pharmacological mechanisms for their action. 
Specifically, the results from our CPP experiments are the first demonstration that CBD 
possess hedonic rewarding properties in the NASh, an effect that was dependent on 5-
HT1A, 5-HT1B and DAergic signaling. Furthermore, intra-NASh CBD administration 
elicited a depression in VTA DA neural activity, a novel electrophysiological effect that 
suggests a potential alternative mechanism for CBD’s well-known antipsychotic 
properties, as well as its ability to oppose the effects of Δ9-THC.  
The results from our olfactory fear conditioning experiments reveal that Δ9-THC 
can potentiate the formation of a subthreshold associative fear memory similar to the 
effect observed with synthetic CB1 receptor agonists. This effect was dependent on 
DAergic receptor signaling; supporting the observation that Δ9-THC elicits increased 
mesolimbic DA transmission. In the same paradigm, CBD was shown to be effective at 
blocking the formation of an aversive fear memory to a normally highly salient 
suprathreshold footshock in a manner similar to that observed with synthetic CB1 
receptor antagonists. This effect was dependent on the  5-HT1A, but not the 5-HT1B, 
receptor signaling mechanism. These results suggest a functional dissociation between 
the neurophysiological mechanisms underlying aversive and appetitive memory 
formation as CBD’s rewarding properties were dependent on 5-HT1B receptor 
transmission in the CPP paradigm. These results also support emerging basic and clinical 
research suggesting the possible use of CBD as an efficacious pharmacotherapy in a 
number of psychiatric disorders such as schizophrenia, PTSD and addiction.         
 The results of these studies suggest many possible avenues for future 
investigation. Future studies should continue our electrophysiology experiments in order 
to characterize the neuroelectrophysiological nature underlying the switch in CBD’s 
motivational valence following 5-HT1A receptor antagonism. Extensions of our olfactory 
fear conditioning experiments should examine electrophysiological changes that may 
occur following intra-NASh Δ9-THC and CBD administration in other areas of the 
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mesocorticolimbic system including the BLA and the mPFC. Finally, although not 
presented in this thesis, preliminary work investigating Δ9-THC reward in the CPP 
paradigm has revealed a strong correlation between the location of Δ9-THC 
microinfusions along the rostral-caudal axis of the NASh and appetitive-aversive 
behavioural reactions to Δ9-THC administration. Follow-up studies should employ 
targeted microinfusions into the rostral and caudal NASh in order to further elucidate the 
nature of this hedonic gradient.       
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